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SCIENTIFIC OPINION 
Scientific Opinion on the evaluation of the safety and efficacy of Cecure® for the removal of 
microbial surface contamination of raw poultry products
1
 
EFSA Panel on Biological Hazards (BIOHAZ)
2 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF)3, 4 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
On request from the European Commission, results of studies submitted with an application for potential 
approval of Cecure® to be used for the removal of microbial surface contamination of raw poultry products 
were assessed to evaluate its safety and efficacy. The proposed treatment consisted of an aqueous solution 
containing cetylpyridinium chloride (CPC) as the active ingredient at a concentration not to exceed 1% and 
propylene glycol (PG), applied by drenching on whole chicken carcasses and recycled after use. Based on the 
available evidence, there is no concern for genotoxicity of CPC. Taking into account the estimated margins of 
safety and the conservative exposure estimates used to assess CPC exposure from consumption of poultry 
carcasses, there are no safety concerns for humans from the proposed use of Cecure®. Based on the information 
provided by the applicant, both Cecure® and CPC were found to be efficacious in reducing contamination with 
pathogenic microorganisms on fresh broiler carcasses. The efficacy of the treatment appeared to be influenced 
more by the concentration of the active ingredient (within the range of 0.2% to 0.5%), than by the volume of 
solution applied, flow rate, spraying pressure, rate of carcass processing, and time of exposure. The data about 
the potential emergence and selection of isolates with reduced susceptibility to biocides and/or resistance to 
therapeutic antimicrobials linked to the use of CPC under the conditions of application, in the recycled solution 
and in the wastewater, were not provided or not considered sufficient for the assessment. Based on the available 
limited data, the intended use of CPC in poultry slaughterhouses would pose risks for the environmental 
compartments surface water, sediment and soil. No risks for the function of sewage treatment plants are 
expected and there are no safety concerns regarding secondary poisoning for birds and mammals, and for 
humans indirectly exposed via the environment. 
© European Food Safety Authority, 2012 
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SUMMARY 
Following a request from the European Commission, the Panel on Biological Hazards (BIOHAZ 
Panel) and the Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF 
Panel) of the European Food Safety Authority (EFSA) were asked to deliver a Scientific Opinion on 
an application dossier submitted by the company Safe Foods Corporation for approval of the use of 
the preparation Cecure® for removal of microbial surface contamination on raw poultry products. 
More specifically, the approval was sought for treatments using an aqueous solution of Cecure® 
consisting of cetylpyridinium chloride (CPC) as the active ingredient and food-grade propylene glycol 
(PG). Cecure® should be applied by drenching at a concentration of less than 1.0% CPC, at room 
temperature, and the solution should be recycled for reuse. 
The Commission asked EFSA to issue a Scientific Opinion on the assessment of the safety and 
efficacy of Cecure® when used to reduce microbial surface contamination on raw poultry products 
(defined as skin-on whole chicken carcasses or parts). Specifically, the task was to consider the 
toxicological safety of the substance, its antimicrobial efficacy, the potential emergence of reduced 
microbial susceptibility to biocides and/or resistance to therapeutic antimicrobials linked to the use of 
the substance, and any risk related to the release of effluents containing the substance from the 
slaughterhouse and/or processing plant into the environment. The assessment was based on the 
guidance document on the submission of data for the evaluation of the safety and efficacy of 
substances for the removal of microbial surface contamination of foods of animal origin intended for 
human consumption published by EFSA5. 
The available data indicate that CPC, formulated as a diluted solution in Cecure®, is not mutagenic in 
bacteria and not clastogenic in cultured mammalian cells. Negative results were also obtained in a 
gene mutation assay with CPC in mouse lymphoma cells and in limited tests in Aspergillus, 
Tradescantia and Drosophila. The CEF Panel also noted that, in addition to these consistently 
negative results, the substance does not contain structural alerts for genotoxicity. Thus, based on the 
available evidence, the CEF Panel considered that there is no concern for genotoxicity. 
The CEF Panel had access to information on subchronic toxicity studies on CPC. From a recent 90-
day toxicity study in Sprague-Dawley rats, the CEF Panel could identify a No-Observable-Adverse-
Effect-Level (NOAEL) of 18 mg/kg bw/day in rats, based on increased caecum weights noted in 
males. The CEF Panel considered the increase in caecum weight as relevant for risk characterisation 
of Cecure® since CPC has been suggested to decrease the total number of microorganisms in the 
caecal contents of rats of both sexes. This led to an increase in caecum to body weight ratios, which 
was positively correlated with dietary levels of CPC. The CEF Panel considered thus that a potential 
similar effect of CPC on human gastrointestinal microflora should not be disregarded. 
The data presented by the applicant allowed the CEF Panel to perform a very conservative risk 
assessment. The potential exposure to CPC was estimated to be up to 5.7 µg/kg bw/day at the mean 
and 17.8 µg/kg bw/day at the 95th percentile of poultry consumption. The potential exposure to PG by 
mean and high level consumers, such as young children would be up to 0.5 µg/kg bw/day at the mean 
and 1.4 µg/kg bw/day at the 95th percentile of treated poultry consumption. These exposure estimates 
are worst cases since they assumed that all poultry carcasses which are going to be consumed have 
been treated with Cecure®. 
                                                     
5  EFSA Journal 2010;8(4):1544 
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Taking into account the highest calculated potential conservative exposure estimates to CPC from 
treated poultry consumption, the margins of safety for CPC would be more than 3000 at the mean and 
more than 1000 at the 95th percentile, when compared to the NOAEL of 18 mg CPC/kg bw/day, 
identified by the CEF Panel in a 13-week toxicity study in Sprague-Dawley rats. For PG, the margins 
of safety would be 22000 at the mean and 7000 at the 95th percentile, when compared to the 
Acceptable Daily Intake (ADI) of 0 - 10 mg/kg bw/day allocated by the Joint FAO/WHO Expert 
Committee on Food Additives (JECFA). Furthermore, they would be 3500 times below the TDI of 5 
mg/kg bw/day established by the Scientific Committee on Food (SCF) for PG. 
Therefore based on the toxicological data available, the estimated margins of safety (going from three 
orders of magnitude for CPC to four orders of magnitude for PG) and the conservative exposure 
estimates used to assess CPC exposure from consumption of poultry carcasses, the CEF Panel 
considers that there are no safety concerns for humans from the proposed use of Cecure® for removal 
of microbial surface contamination from raw poultry under the usage conditions specified in this 
opinion.  
A total of 15 peer reviewed published papers and 13 in-house studies dealing with testing of CPC or 
Cecure® for decontamination efficacy were submitted. Based on selection criteria, five peer-reviewed 
published papers and eleven in-house studies were selected and used in the assessment of the efficacy 
of Cecure® by the BIOHAZ Panel.  
The selected studies were classified as high, medium or low strength of evidence, based on the 
experiment setting (industrial scale, pilot plant or laboratory) and on the type of microbial 
contamination of the analysed samples (naturally contaminated or inoculated). 
Based on results published in peer-reviewed papers and in-house conducted studies, mostly performed 
at industrial scale and on naturally contaminated samples, both Cecure® and its active ingredient CPC 
were found to be efficacious in reducing contamination with pathogenic microorganisms on fresh 
broiler carcasses or chicken skin. The microbial reductions achieved on pre- and post-chill treated 
samples were in the range of <1.0 to 5.0 log units over untreated and water-treated controls. The 
lower reductions were generally associated with lower concentrations of CPC (e.g., 0.1% or 1 mg/ml 
CPC) applied to samples of low initial contamination, while the higher reductions were achieved with 
inoculated samples.  
The BIOHAZ Panel further concluded that the efficacy appeared to be influenced more by the 
concentration of the active ingredient than by the volume of solution applied, flow rate, spraying 
pressure, rate of carcass processing, and time of exposure within the ranges examined. Since the 
Cecure® solution is to be recycled after use, the BIOHAZ Panel assessed the level of efficacy of the 
recycled solution, and concluded that there is inadequate evidence to support that the recycled 
Cecure® solution is as efficacious as the fresh solution and that it does not accumulate resistant 
bacterial cells and/or spores.  
Data to address the issue of the potential emergence and selection of isolates with reduced 
susceptibility to biocides and/or resistance to therapeutic antimicrobials linked to the use of CPC were 
not provided. Moreover, no tests were undertaken by the applicant to test for the potential 
development of resistance of the target organisms either under the conditions of use, or in wastewater. 
The data provided were not considered useful to support the absence of antimicrobial activity of CPC 
in organic material. Further, evidence was not provided about testing potential microbial 
contamination of Cecure® solution in the recycling process for all bacterial species.  
Concerning the risk related to the release of CPC into the environment as a result of use of Cecure®, 
basic data necessary for an assessment of the environmental compartments surface water, sediment 
and soil, as well as for evaluation of the function of sewage treatment plants, were not submitted or 
could not be validated. Therefore, data on the toxicity, fate and behaviour of CPC found in the open 
literature were used to perform a preliminary risk assessment.   
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The predicted environmental concentrations (PECs) and predicted no-effect concentrations (PNECs) 
for protection of the function of sewage treatment plants (STP) for surface water, as well as for 
sediment and soil, were derived using the software system EUSES 2.1.1 which has been developed for 
quantitative assessment of the risks of biocides and industrial chemicals to man and the environment. 
This system is fully based on the EU Technical Guidance Documents (TGD) for the risk assessment 
of these chemicals.  
A comparison of PECs with the PNECs suggests that the use of CPC in poultry slaughterhouses does 
not pose a risk for the function of sewage treatment plants. As there are no indications of a high 
bioaccumulation potential, no risk for birds and mammals in the environment via indirect exposure 
through the food-chain (secondary poisoning) has to be expected. In view of the low vapour pressure, 
low bioaccumulation potential and the high adsorptive properties of CPC, indirect exposure of man 
via groundwater (as a source for drinking water), air and fish is expected to be negligible.  
Despite the fact that it is assumed that a large proportion of the active ingredient is recycled and that 
the product is assumed to be used in a specific application system claimed by the applicant, risks for 
the environmental compartments surface water, sediment and soil are apparent.  
It is recommended that, as requested in the EFSA guidance (EFSA, 2010), data addressing the 
potential emergence of and selection for reduced susceptibility to biocides and or resistance to 
therapeutic antimicrobials linked to the use of CPC should be provided by the applicant. Moreover the 
minimum CPC concentration applied for should be specified, and data about possible accumulation of 
bacterial spores, as well as data to support continuous efficacy of the recycled solution should be 
collected.  
In order to improve the robustness and reduce the uncertainty of the assessment, the CEF Panel 
recommends to the applicant to provide more reliable data on the environmental fate and behaviour of 
CPC and to provide (long-term) tests relevant for the compartments surface water, sediment and soil. 
However, considering the high level of potential risk indicated by the present assessment, it is the 
opinion of the CEF Panel that the attainment of safe environmental levels would be highly unlikely 
without suitable measures to reduce environmental emissions. An option would be to reduce exposure 
by achieving a high proportion of recycling during treatment in poultry slaughterhouses. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The EU food hygiene legislation is aimed at protecting consumers against potential risks to health and 
maintaining a high level of consumer protection at all stages of the food chain. That objective must be 
achieved by applying the appropriate measures, including good hygiene practices and hazard control 
measures at each step of the food chain. 
According to EU scientific advice6, decontamination practices can constitute a useful tool in further 
reducing the number of pathogenic microorganisms but the use of substances intended to remove 
microbial surface contamination should only be permitted if a fully integrated control programme is 
applied throughout the entire food chain. Those substances shall be assessed thoroughly before their 
use is authorised.  
Article 3 (23 of Regulation (EC) No 853/2004 provides a legal basis to approve the use of substances 
other than potable water to remove surface contamination from products of animal origin.  
In addition to the safety of the substance, the potential emergency of reduced susceptibility to biocides 
and/or resistance to therapeutic antimicrobials is also a matter of concern as well as the impact of the 
substance or its by-products on the environment.  
Therefore, before taking any risk management decisions on their approval, a risk analysis process 
should be carried out taking into account the result of a risk assessment based on the available 
scientific evidence and undertaken in an independent and transparent manner. 
EFSA GUIDANCE  
On 14 April 2010, the European Food Safety Authority (EFSA) issued a revision of a guidance 
document7 on the submission of data for the evaluation of the safety and efficacy of substances for the 
removal of microbial surface contamination of foods of animal origin intended for human 
consumption. 
APPLICATION FOR APPROVAL 
On 14 March 2011, the Commission received an application dossier from the company Safe Foods 
Corporation for the approval of the substance Cecure® for uses to reduce microbial contamination of 
raw poultry products. According to the dossier, Cecure® is an aqueous solution containing 
cetylpyridinium chloride as the active ingredient, and food-grade propylene glycol. 
TERMS OF REFERENCE AS PROVIDED BY EUROPEAN COMMISSION 
EFSA is requested to evaluate the safety and efficacy of Cecure® to remove microbial surface 
contamination of raw poultry products, considering: 
1. the toxicological safety of the substance; 
2. the efficacy, i.e. does the use of the substance significantly reduce the level of contamination 
of pathogenic micro-organisms; 
3. the potential emergence of reduced susceptibility to biocides and/or resistance to therapeutic 
antimicrobials linked to the use of the substance; 
                                                     
6  SCVPH (Scientific Committee On Veterinary Measures Relating To Public Health), 1998. Report on the benefits and 
limitations of antimicrobial treatments for poultry carcasses, 30 October 1998. SCVPH (2003) Opinion on the evaluation 
of antimicrobial treatments for poultry carcasses (http://ec.europa.eu/food/fs/sc/scv/out14_en.pdf ). 
7   EFSA Journal 2010;8(4):1544 
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4. The risk related to the release of the slaughterhouse and/or processing plant effluents, linked 
to the use of the substance, into the environment. 
 
APPROACH TAKEN TO ANSWER THE TERMS OF REFERENCE 
In order to assist in assessing the safety and efficacy of a proposed decontaminating agent of foods of 
animal origin, EFSA issued in 2010 a revised guidance document titled “Revision of the joint 
AFC/BIOHAZ guidance document on the submission of data for the evaluation of the safety and 
efficacy of substances for the removal of microbial surface contamination of foods of animal origin 
intended for human consumption” (EFSA, 2010). The document presents the major components and 
data that an application dossier should contain. These guidelines, terminology and procedure have 
been used in this Scientific Opinion for the assessment of Cecure® for use in the decontamination of 
raw poultry products. 
After having received this request from the European Commission, EFSA assigned the mandate to the 
Panel on Biological Hazards (BIOHAZ Panel) and the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (CEF Panel). Chapters 3 and 4 were adopted by the BIOHAZ Panel 
on 8th March 2012. Chapter 2 and 5 and the respective conclusions were adopted by CEF Panel on 21st 
March 2012. 
The term “raw poultry products” is defined as whole chicken carcasses, as referred in the dossier and 
in the studies provided by the applicant. In one chapter of the dossier, turkey carcasses are also 
mentioned (page 158 of the dossier), but that study concerns the general slaughtering process, and is 
not related to the use of Cecure® for decontamination. Only one study (Baker et al., 2010) evaluated 
the shelf-life of chicken parts, boneless skinless breast meat, thighs, wings, split breasts and leg 
quarters, derived from treated carcasses. The laboratory studies by Arritt et al. (2002) and Breen et al. 
(1997) evaluated chicken skin samples and the ability of cetylpyridinium chloride (CPC) to inactivate 
Campylobacter jejuni and Salmonella typhimurium, respectively. 
ASSESSMENT 
1. Introduction 
Approval was sought for removal of microbial surface contamination from raw poultry products by the 
use of an aqueous solution containing CPC as the active ingredient, and food-grade propylene glycol 
(“PG”), with the function to maintain the solubility and stability of the solution. The mixture has the 
trade name Cecure®. As proposed, Cecure® is to be diluted to < 1% concentration of the active 
ingredient in potable tap water for use as a decontaminant treatment for raw poultry in a drenching 
application cabinet which is part of the Cecure® application system that “captures and recycles 
virtually all solution”. 
Relative to the purpose of the treatment, the dossier indicates: Cecure® will be used as a food 
processing aid to control the following organisms on raw poultry carcasses and skin-on poultry parts: 
Salmonella, Campylobacter, Listeria, Staphylococcus aureus, Escherichia coli (including O157:H7), 
Pseudomonas, total coliforms, viruses, and other naturally-occurring microorganisms on raw poultry 
carcasses (page 12 of the dossier). 
1.1. Parameters for treatment application 
The applicant includes the following information in the dossier (pages 16-21): 
 Where in processing line: Cecure® can be used to treat the inner and outer surfaces of raw 
pre-chill, skin-on poultry carcasses after the last inside/outside bird washer. Optionally, it can 
be applied post-chill to skin-on whole poultry carcasses or to skin-on parts.  
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 Concentration: The concentrated solution Cecure® is diluted on-site with potable water to 
reach a concentration, for which the approval is sought, not to exceed 1.0% CPC (10 mg/ml) 
in the final solution. It is stated that a processor is likely to apply a solution with a CPC 
concentration ranging from 0.2% to 0.5% (2.0 to 5.0 mg/ml CPC) depending on point of 
application.  
 Conditions of use: neutral pH, at ambient temperature. 
 Application: as a drench in a cabinet equipped with spray nozzles and a booster pump 
allowing application of the liquid at a constant volume in litres per minute (Figure 2, page 19 
in submitted dossier). Drenching is different from spraying applications because drenching 
uses larger nozzles sizes, which produce thicker jets, and the larger volumes of liquid floods 
and soaks the carcasses. 
 Exposure time: only a few seconds, typically (not limited to) ≤ 5 seconds for whole carcasses 
or up to (but not limited to) 20 seconds for skin-on parts. 
 Volume to apply: the treatment volume will be in the range, but not limited to, approximately 
1.0 to 2.0 litres per carcass. 
 Subsequent removal conditions: the carcasses are treated with a potable water rinse (if 
carcasses are not immersion chilled); in the dossier it is indicated that typically a “very low” 
volume rinse is applied. 
 Recycling: a recycling step is foreseen in the application. According to the dossier, the CPC 
concentration in the recycled solution is monitored in the Cecure® application system. It is 
stated that there is no decrease in efficacy when using Cecure® solution consisting entirely of 
drip recycled from treated carcasses. Bacterial contamination of Cecure® usage solution is 
reported in the dossier not to occur under the proposed conditions of use. 
1.2. Cecure® application as related to carcass chilling  
The applicant also provides the following details in the dossier (pages 160-162): 
 After inspection and viscera removal, the carcasses are washed inside and outside as they pass 
through three or four inside/outside bird washers (IOBWs). These stainless steel cabinets are 
automated washing stations for the carcasses. Several gallons (litres) of water are used to 
clean each individual carcass – inside and out. All of the water used in these wash cabinets is 
directed to the offal line.  
 Following processing through the IOBWs, carcasses may be treated with Cecure® just prior to 
chilling (pre-chill treatment). The carcasses then move via the overhead shackle line to the 
chilling phase of the process.  
 Immersion Chilling. In immersion chilling, the carcasses are dropped automatically from the 
shackle line into a huge tank of water called the pre-chiller. This tank typically contains 
30,240 litres of water held at 10° to 13°C. The carcasses typically remain in the pre-chiller for 
about 15 minutes.  
 From the pre-chiller tank, the carcasses move automatically into the chiller tank. This tank is 
larger, containing 94,500 litres of colder water, usually 0° to 1°C, and the carcasses stay in 
this tank for about 45 minutes. USDA/FSIS, as well as the regulatory agencies in most other 
countries, require that the carcasses exiting the final chiller have an internal muscle 
temperature of ≤ 4.4°C.  
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 Air Chilling. During air-chilling, carcasses move on shackles through a cold room at 0° to 1°C 
for 90 to 130 minutes. The carcasses are misted with water prior to and periodically during the 
air-chilling process. As in immersion chilling, the internal temperature of the muscle must be 
≤ 4.4°C at the exit of the air-chilling room.  
 After immersion or air-chilling, carcasses are transported to other areas of the plant. They may 
move to a whole carcass packaging station, may go to a separate part of the plant for cut-up or 
deboning, or may be shipped to a different plant for further processing or cooking.  
 Application of Cecure®: As mentioned above, the current clearance for CPC in the U.S. 
permits its use on pre-chill poultry carcasses or on post-chill poultry carcasses or skin-on 
poultry parts. Each application (pre- or post-chill) is discussed below in terms of 
environmental impact.  
o Pre-chill use: For pre-chill use of Cecure® as described in the dossier, i.e., ≤ 1.0% 
for whole skin-on carcasses that will be immersion or air-chilled, the Cecure® drench 
application cabinet is positioned just after the last IOBW. In plants that utilize air-
chilling, Cecure®-treated carcasses are rinsed with potable water before entering the 
air-chilling room as they travel at the processing line speed in place at the plant. The 
carcasses then continue along the processing line to the air-chilling room.  
o Post-chill use: For post-chill application of Cecure®, carcasses are treated after 
removal from the final immersion chiller tank or after they exit the air-chilling room. 
The carcasses then receive a potable water rinse (regardless of chilling method, i.e., 
immersion or air-chilling), again travelling at the processing line speed in place at the 
plant. The carcasses then continue along the line for further processing and/or 
packaging.  
The aim of the present opinion is to assess the safety and efficacy of Cecure® to reduce microbial 
surface contamination on raw poultry products considering (i) the toxicological safety of the 
substance, (ii) the efficacy, i.e. does the use of the substance significantly reduce the level of 
contamination of pathogenic microorganisms, (iii) the potential emergence of reduced susceptibility to 
biocides and/or resistance to therapeutic antimicrobials linked to the use of the substance, and (iv) the 
risk related to the release of the slaughterhouse and/or processing plant effluents, linked to the use of 
the substance, into the environment. Each of these assessments is described subsequently. 
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2. The toxicological safety of the formulated product to humans  
2.1. Evaluation 
2.1.1. Technical data 
2.1.1.1 Identity of the substance and specifications 
Cetylpyridinium chloride (CPC) 
 
Synonyms: 1-palmitylpyridinium chloride, C16-alkylpyridinium chloride, 
Acetoquat CPC, Aktivex, Ammonyx CPC, Cepacol, Ceprim, 
Cetafilm, Halest, Ipanol, Medilave, Mercocet, Merothol, and Pionin 
B. 
 
Common names: Ceepryn chloride, Cepacol chloride, Cetamium, Dobendan, Pristacin, 
and Pyrisept.  
Chemical name:  1-hexadecyl pyridinium chloride 
CAS Registry Number:  123-03-5 (anhydrous) and 6004-24-6 (monohydrate) 
EC number:   204-593-9 
Chemical formula:   C21H38NCl 
Molecular weight:  340 g/mol 
Structural formula:               
CPC is typically present in the monohydrate form C21H38NCl:H2O with a molecular weight of 358 
g/mol. The calculated elemental content is C: 70.45%, H: 11.26%, Cl: 9.90%, O: 4.47%, and N: 
3.91%. 
Description:  
CPC is a white powder, with a melting point of 77°C in anhydrous form and 83°C in its monohydrate 
form.  It is freely soluble in water, alcohol and chloroform, but is hardly soluble in benzene and ether. 
The log octanol-water partition coefficient (log Ko/w) is 1.71. 
Propylene glycol (PG) 
 
Synonyms: α-propylene glycol, 1,2-propanediol, 1,2-Dihydroxypropane, methyl 
ethyl glycol (“MEG”), methylethylene glycol, PG, Sirlene. 
Chemical name:  Propane-1,2-diol  
CAS Registry Number:  57-55-6 
EC number:   200-338-0 
Chemical formula:   C3H8O2 
Molecular weight:  76.09 g/mol 
Structural formula:       
  
Safety and efficacy of Cecure® decontamination of raw poultry products 
 
EFSA Journal 2012;10(3):2162 12 
PG is authorised as a food additive E 1520 (Commission Regulation N° 1129/20118). 
Description:   
PG is a colourless, clear, hygroscopic, viscous liquid. PG has a melting point of -59°C, a boiling point 
of 188.2°C, and is freely soluble in water, ethanol and acetone. 
Other specifications of CPC 
Purity: The applicant does not manufacture CPC. A manufacturer provided the US Pharmacopeia-
grade CPC to the applicant with a certificate of analysis in compliance with the specifications. The 
quality of CPC used for the preparation of Cecure® may contain very low levels of pyridine (70-120 
mg/kg CPC as stated by the applicant) as a residual starting reactant from the synthesis of CPC. At the 
requested use level as proposed by the applicant, pyridine cannot be detected (at a detection level of 1 
mg/L). No other known impurities, by-products, contaminants or reaction products of concern have 
been reported by the applicant in CPC by using liquid chromatography-mass spectrometry (LC-MS). 
Stability: The applicant assayed the stability of CPC solutions, from the commercial Cecure® solution 
of known concentration in water, by determining pyridine as the potential breakdown product. The 
solutions were heated to 95°C for 10, 20, 30, 60, or 90 minutes. After heat treatment, the solutions 
were analyzed for free pyridine using LC/MS with a sensitivity of 1 ng/mL. Results demonstrated 
there was no release of free pyridine in the heated solutions and no other reaction products were found. 
The applicant also analysed CPC for hexadecene and cetyl chloride during storage for several years 
and no detectable amount of either compound was found with methodology sensitive to 0.05%. 
Description of the product to be used, conditions of storage and shelf-life: Cecure® is a food 
processing aid, supplied as a concentrate solution of CPC dissolved in an aqueous solution with PG. 
Cecure® concentrate solution is recommended by the applicant to be stored at temperatures above 
18ºC to avoid crystallization of CPC in the solution. However, if crystallization occurs, it is claimed 
that the solution can be heated to restore its viscosity without degradation of the Cecure® solution. 
The stability of CPC under normal storage conditions (4°C, 20°C, and 48°C, as well as after freezing 
and thawing) was ensured by the applicant through analytical data on production batches. The results 
showed acceptable CPC assay, melting range, and moisture content for five years from the date of 
manufacture. 
Description of chemical reactivity of the substance under intended conditions of use: The carbon-
nitrogen (C-N) bond attaching the aliphatic carbon tail to the pyridine ring in CPC is very strong and 
would require strong oxidants, not routinely used within poultry processing plants, to disrupt the 
bonds. The aliphatic carbon tail is saturated and thus contains a uniform electron distribution that 
would greatly hinder nucleophilic attack by chemicals typically present in poultry processing and 
rendering plants.  
Previous evaluations and authorizations: Cecure® is approved for use as decontaminant treatment for 
raw poultry carcasses and skin-on poultry parts in the USA by the US Food and Drug Administration 
(FDA) and by the United States Department of Agriculture/Food Safety Inspection Service 
(USDA/FSIS). Cecure® is also approved in other countries, including Canada, Mexico, Panama, 
Costa Rica, Colombia, Russia, South Africa, Saudi Arabia, and Jordan.  CPC is a cationic quaternary 
ammonium compound found in many types and brands of worldwide, commercially available 
products such as mouthwash, toothpaste, lozenges, throat sprays and anti-snore throat sprays, as well 
as baby teething gels and baby wipes. 
                                                     
8  Commission Regulation (EU) No 1129/2011 of 11 November 2011. Official Journal of the European Union L295/177  
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2.1.1.2 Manufacturing process 
The substance is not manufactured by the applicant. It is available commercially from different 
suppliers.  
According to the applicant, CPC can be prepared by the interaction of cetyl chloride and pyridine 
under pressure at an elevated temperature. In aqueous solution, CPC is synthesized by alkylation of 
pyridine with cetyl chloride to yield the monohydrate of the quaternary salt of pyridine and cetyl 
chloride. The product is supplied with a certificate of analysis of the manufacturer. 
2.1.1.3 Reactions and fate of the decontaminating agents of the formulated product on the treated 
foods of animal origin 
Quantification of residual levels of the substance in the treated food: The applicant assayed 5 trials, for 
pre or post-chill treatments, with or without use of brushes, with a variety of CPC concentrations in 
the application solution (0.05% to 2% CPC) and varying volumes of treatment solutions (1.2 to 7.6 L 
per bird) followed by potable water rinsing. The amount of CPC that was absorbed in the skin of 
chicken carcasses after those treatments with typical Cecure® solutions at different final 
concentrations of use was reported by the applicant to be within the range 2.9 – 25.9 mg/kg poultry 
skin, the higher concentrations being reported for the post-chill treatments. It was reported that no 
CPC residues could be detected in the meat (with a detection limit of 0.19 µg/g). 
The residues of propylene glycol (PG) in the carcass were also assayed by the applicant. The PG 
residue on pre- and post-chill treated carcasses ranged from 0.9 mg/kg to 2.1 mg/kg, including both 
samples that were rinsed and samples that were not rinsed before analysis. It was reported that no PG 
residues could be detected in the meat. 
Degradation products of the substance: The applicant reports that due to its structural nature, CPC is 
resistant to breakdown and subsequent generation of degradation products, as a result of operational 
steps performed routinely within poultry processing and rendering plants. The application of 95°C for 
up to 60 minutes or indirect steam to treated chicken samples did not alter the HPLC results. Typical 
cooking procedures, like baking and frying, were also tested by the applicant. Nine poultry drumsticks 
were baked at 190.6ºC in an oven for 45 min and 9 other poultry drumsticks were fried in vegetable oil 
heated to 175ºC for 20 min. Based on the similar CPC recovery and the respective chromatograms for 
both cooking procedures, it can be concluded that no degradation or reaction products were formed. In 
the case of PG, the applicant reports that it does not break down on the treated food or in the 
processing environment. 
Description of any reaction by-products resulting from potential reactions with natural compounds in 
the food during and after treatment: As described above, degradation of CPC is not expected as a 
result of the intended use. Considering the chemical nature of CPC, no oxidative or acid catalysed  
reactions with lipids, proteins or carbohydrates are to be expected.  
2.1.1.4 Methods of analysis  
The analytical method to detect residues of CPC in poultry is based on HPLC with UV detection while 
the analysis of PG is based on Gas Chromatography. The limit of detection for CPC is reported by the 
applicant to be 0.19 µg/g. The CEF Panel notes that the analytical methods for CPC and PG have been 
validated with spiked samples and described in detail by the applicant. The analytical methodology to 
detect pyridine in the study of heat treatment stability of CPC is based on LC-MS and the limit of 
detection for pyridine is reported by the applicant to be approximately 1 ng/mL. 
2.1.2. Dietary exposure assessment of CPC resulting from use as a decontaminating agent 
Information on estimated residue levels of CPC and PG in the skin of chicken carcasses was provided 
in the dossier. The amount of CPC that can be absorbed in the skin of chicken carcasses from different 
treatment conditions has been reported to be within the range 2.9 – 25.9 mg/kg poultry skin.  
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To estimate the skin weight as a percentage of the carcass weight, the applicant used data from 5 trials 
reporting skin weight versus average carcass weight and average live weight for birds processed in the 
USA in 2005. The average carcass weight for each trial was calculated by the applicant as the 
multiplication of the average live weight for that trial by the estimated percent yield for carcasses of 
that size, as provided by the management personnel in the processing plants where the trials were 
conducted. The applicant provides an estimate of 8.8 % of skin in relation to total weight of the 
carcass. Taking into account 25.9 mg/kg skin as the worst case of CPC residue content in the skin, the 
average concentration of CPC per kg of poultry which is consumed with the skin on would be 2.3 
mg/kg poultry.  
The applicant provided an estimation of the consumption of poultry in the European Union based on 
the UK, as the country consuming the largest amounts of poultry within the EU, and dividing such 
consumption by the total UK population. This is not considered as representative of worse case 
consumption because not all the population consumes poultry and, in addition, high consumers of 
poultry were not taken into consideration. So, a new consumer exposure assessment was performed 
based on the EFSA European food consumption databases (EFSA, 2011b). The consumption of 
poultry for mean and high level consumers (at the 95th percentile), such as young children in an EU 
country with high poultry consumption like Bulgaria, was 2.5 and 7.8 g/kg bw/day, respectively 
(EFSA, 2011b).  
On this basis, the potential exposure to CPC would be up to 5.7 µg/kg bw/day at the mean and 17.8 
µg/kg bw/day at the 95th percentile of treated poultry consumption. In the case of PG, the residual 
values that can be absorbed in the skin of chicken carcasses are within the range 0.9 mg/kg to 2.1 
mg/kg. Taking the last value as the worst case, the residual PG content for the full carcass would be 
0.2 mg/kg poultry. The potential exposure to PG by mean and high level consumers, such as young 
children in Bulgaria, as described above, would be up to 0.5 µg/kg bw/day at the mean and 1.4 µg/kg 
bw/day at the 95th percentile of treated poultry consumption. 
2.1.3. Toxicological data 
This section deals with the evaluation of the safety of Cecure® commercial product, containing CPC 
as active ingredient for the removal of microbial surface contamination from raw poultry carcasses, 
under the usage conditions specified in this opinion.   
From the information available, it can be concluded that CPC has not been evaluated previously as a 
food ingredient, although CPC has been evaluated as part of pharmaceutical formulations or oral 
cavity drug products as described in the following section. 
The EFSA guidance for the evaluation of the safety and efficacy of substances for the removal of 
microbial surface contamination of foods of animal origin intended for human consumption (EFSA, 
2010) does not stipulate a fixed set of toxicological studies. The full reports of the following studies 
were provided by the applicant:    
- A bacterial mutagenicity assay on Cecure® commercial product 
- An in vitro Chromosome Aberration in Chinese Hamster Ovary Cells for Liquids on CPC  
- A 14-day palatability study of CPC in Sprague-Dawley rats  
- A 28-day short-term toxicity feeding study of CPC in Sprague-Dawley rats  
- A 28-day toxicity feeding study of CPC in Beagle dogs  
- A 90-day toxicity feeding study of CPC in Sprague-Dawley Rats  
- A 90-day toxicity feeding study of CPC in Beagle Dogs 
In addition, the applicant provided bibliographic references or summaries of a series of toxicological 
studies, reports and scientific papers addressing several endpoints: genotoxicity, acute oral toxicity, 
short-term and subchronic toxicity, chronic toxicity and carcinogenicity, reproductive and 
developmental toxicity of Cecure® or CPC. The Panel is aware that additional data on the toxicology 
of CPC (including genotoxicity and reproductive toxicity) have been generated within the context of 
data requirements for biocides. However, these data were not available to EFSA. 
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A thorough evaluation of the scientific reliability and robustness of all the studies provided was done 
and is described below. 
2.1.3.1 Acute oral toxicity 
LD50 values of 200 to 681 mg CPC/kg bw in rats, of 125 mg/kg bw in mice and of 400 to 500 mg/kg 
bw in rabbits have been reported (BIBRA, 1988; Genco, 1995). LD50 values of 99 to 159 mg/kg bw 
were reported for male mice whereas values of 286-406 mg/kg bw for rats were reported in other 
reports (USAEH-HT, 1969). An LD50 value of 400 mg/kg bw in rats (males and females combined) 
has also been reported (Zeeland Chemicals Inc., 1995). In a study involving groups of   3 or 10 or 13 
Sprague-Dawley male rats given solutions containing 100, 200, 250, 300, 350, 400 and 450 mg 
CPC/kg bw a LD50 of 200 mg/kg bw was reported (Nelson & Lyster, 1946). 
Effects such as limb paralysis were reported at high (unspecified) doses of CPC, while doses of 400 
mg/kg bw caused diarrhoea (BIBRA, 1988). More pronounced effects on the central nervous system 
(CNS) were reported following CPC administration via intravenous or intraperitoneal routes but these 
routes of administration do not appear relevant to the intended uses in the application. 
Safety profile sheets on CPC monohydrate in the application dossier mention that the compound is 
poisonous by ingestion, intraperitoneal, intravenous and subcutaneous routes (Lewis, 1996). 
One publication mentions that fatal doses for quaternary ammonium salts in humans by ingestion can 
be estimated to be between 1 and 3 grams. The principal manifestations of human poisoning from 
ingestion of quaternary ammonium salts are vomiting, collapse and coma due to caustic effects (Arena 
& Drew, 1986). 
2.1.3.2 Short-term and subchronic toxicity 
Orally administered CPC to rats and dogs at doses of 5 to 500 mg/kg bw/day were reported to cause 
morbidity and death at 125, 250, and 500 mg/kg bw/day (no more details available). At lower doses 
(50 mg/kg bw/day) gastric irritation was reported (Genco, 1995). 
One subchronic toxicity study done in the 1940‟s on CPC is summarised in a report document 
submitted to FDA‟s over-the-counter (OTC) Review Panel on Oral Cavity Drug Products (Procter & 
Gamble, 1979). Groups of 6 or 10 or 12 rabbits were administered orally 0, 10 or 100 mg/kg bw of 
CPC for 28 days. No overall effects on body weight gain were reported, although the animals that lost 
weight showed temporary diarrhoea (no more details). No evidence of gross pathological changes was 
reported. Histological examination reported varying degrees of diffuse vacuolisation of the cytoplasm 
of liver cells in both control and treated groups. Similar findings were reported in the cytoplasm of 
kidney cells lining the tubules in all groups, more pronounced in the high-dose group. The authors 
considered these findings as not toxicologically significant. 
In a 14-day palatability study, groups of 5 Sprague Dawley rats of both sexes were administered 0, 
100, 500, 1000, 1500 and 2000 ppm of CPC orally in the diet, equivalent to 0, 5, 25, 50, 75 and 100 
mg/kg bw/day (Redfield Laboratories, 2001a). The study was done under GLP conditions according to 
international guidelines. Regular observations included clinical parameters, body weights and feed 
consumption. Thinness was observed in one female from the highest dose group (100 mg/kg bw/day), 
the effect correlated with lower feed consumption and was considered treatment related. No other 
adverse findings were reported upon clinical observations. Overall, there was a treatment-related 
decrease in body weight gains in male and female rats, starting in animals in the 50 mg/kg bw/day 
group for the males and in the 75 mg/kg bw/day group for the females. Over the duration of the study 
a treatment-related decrease in feed consumption beginning in males and females from the 25 mg/kg 
bw/day group was reported. The effect was statistically significant starting at the 50 mg/kg bw/day  
group animals only, although a clear trend in decreased feed intake was observed at all doses when 
compared to controls. 
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In a 28-day study, groups of 10 Sprague Dawley rats of both sexes were administered 0, 125, 250, 
375, 500, 750 and 1000 ppm of CPC orally in the diet, equivalent to 0, 6.25, 12.5, 18.7, 25, 37.5 and 
50 mg/kg bw/day (Redfield Laboratories, 2001b). The study was done under GLP conditions 
according to international guidelines. Observations included body weights and feed consumptions 
measured weekly. Haematology, clinical chemistry and urinalysis were evaluated at termination. All 
animals underwent gross necropsy and specific tissues underwent histopathology examination. No 
adverse clinical observations were reported. Body weights and body weight gains were significantly 
lower in males and females 37.5 and 50 mg/kg bw/day groups. These effects were considered 
treatment-related and were attributed to a direct effect on feed consumption. Similar findings were 
reported in animals from the remaining treated groups but they were inconsistent. A dose-related 
decrease in feed consumption was reported in males and females from 37.5 and 50 mg/kg bw/day 
groups. Feed consumption was also reduced in females from the 18.7 and 25 mg/kg bw/day groups. 
No ophthalmological abnormalities were reported. There were some changes in the haematology, 
clinical chemistry, including lower total bilirubin concentration at all doses in females and higher 
glucose and higher aspartate aminotransferase activity in males from the 50 mg/kg bw/day mg/kg 
bw/day group. Urinalysis parameters examined showed inconsistent changes across sexes. Several 
differences in absolute and relative organ weights in males and females were reported without 
histopathology changes.  In males, statistically significant increases in weight of adrenal glands, brain, 
caecum and testes, relative to body weight, was observed in  the 50 mg/kg bw/day group. In the case 
of caecum and testes, there was a consistent dose-related increase in weight, relative to body weight, 
in males, although it only became significant from the 37.5 and the 50 mg/kg bw/day groups, 
respectively. In females, statistically significant increase organ weight, relative to body weight, were 
observed in adrenal glands (25 mg/kg bw/day group), brain (18.7 and 50 mg/kg bw/day groups), 
kidneys (37.5 and 50 mg/kg bw/day groups) and caecum (18.7, 37.5 and 50 mg/kg bw/day groups). 
For caecum relative weights, there was a consistent dose-related increase, although not statistically 
significant, at the 25 mg/kg bw/day dose.  
Groups of 15 or 20 Weanling rats per sex were administered 0, 5, 10 or 20 ml of a solution containing 
CPC and domiphen bromide at a ratio of 9:1 (Procter & Gamble, 1979). Relative liver weights were 
reported as significantly higher in all treated male rats than in the water control animals. The females 
from the middle and high dosage groups were also reported to show significantly higher relative liver, 
kidney, and adrenal glands weights. The authors concluded that these changes could not be attributed 
to the active ingredients, based on the finding that the values for these parameters were not 
significantly different to those in the ethanol control animals. No other treatment related effects on 
haematological parameters or urinalysis where reported. Significant decreases in serum alkaline 
phosphatase and albumin serum levels were reported in all treated male rats, these were reported as 
not dose-related. No gross and histological findings in tissues were reported as treatment-related. The 
relevance of these findings in the evaluation of the safety of CPC is questionable, given that it was 
administered as a mixture with another compound.  
Groups of six rats (strains not specified) of both sexes were administered in the diet 0, 125, 300, 800, 
2000, 5000, 10000 ppm CPC (equivalent to approximately 0, 6.25, 15, 40, 100, 250 and 500 mg/kg 
bw/day) for 90 days (USAEH-HT, 1969). All animals administered 250 mg/kg bw/day and 500 mg/kg 
bw/day died within three weeks after initiation of the test. An significant increase in caecum to body 
weight ratios, when compared to controls, was reported in female rats in the 15 mg/kg bw/day, 40 
mg/kg bw/day and 100 mg/kg bw/day groups, as well as in males in the 40 and 100 mg/kg bw/day 
groups. It was noted that, as the concentration of CPC increased, the total number of microorganisms 
in the caecal contents decreased, in both sexes. A positive correlation was noted between dietary levels 
of CPC and increases in caecum to body weight ratio. Unspecified differences in body weight gain, 
liver and kidney to body weight ratios and food utilisation of male and female rats in the 100 mg/kg 
bw/day group were reported. Gross and microscopic examination of liver, kidneys, lung, spleen, 
caecum and testis from any of the administered groups were reported to show no appreciable 
differences compared to controls. 
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BIBRA summarised two studies done on rats and rabbits with CPC (BIBRA, 1988), one of these 
studies presumably was the same as that described above. BIBRA described these studies as follows: 
Groups of six rats of both sexes (strains not identified) were given diets containing up to 1.0 % CPC 
for 90 days, equivalent to approximately 500 mg/kg bw/day. All animals given 0.5 % (~250 mg/kg 
bw/day) and above, died within 3 weeks. It is reported that no gross effects or changes in organ 
weights were seen in the group administered approximately 6.25 mg/kg bw/day (0.0125%). Increased 
caecum weights were reported in females administered 0.03 % (~15 mg/kg bw/day) and above and in 
males administered higher than 0.06 %. (~30 mg/kg bw/day). Adverse effects on growth and 
(unspecified) changes in liver and kidney weights were seen at 0.2 % (~100 mg/kg bw/day). The liver, 
kidneys, lungs, spleen, caecum and testes were normal upon microscopic examination. 
Groups of 10 to 12 rabbits administered 10 to 100 mg/kg bw/day for 4 weeks (presumably by gavage) 
showed no gross treatment-related abnormalities. Upon microscopic examination, there was limited 
evidence of mild effects in the kidney and liver at all doses, although similar less severe findings in 
controls (unspecified) led the investigators to express doubts that they were treatment-related. 
Groups of two or four dogs (breed not identified) were administered by gavage single daily doses of a 
pharmaceutical formulation containing CPC, benzyl alcohol, liquid glucose and sucrose for 30 days 
(Scientific Laboratories, 1969a). The groups were described as control (distilled water), group II dosed 
1 ml/kg bw/day, group III 3 ml/kg bw/day and group IV 10 ml/kg bw/day. It is reported elsewhere that 
the pharmaceutical formulation contains per dosing 1.47 mg cetylpyridinium, 6.5 mg benzyl alcohol, 
1.1 g liquid glucose and 1.2 g sucrose (Cepacol ®). In the absence of specific information, it is 
assumed that the same concentrations per ml were tested in this study. The animals underwent clinical 
laboratory determinations as well as complete necropsy and histopathological examinations. 
According to the authors‟ conclusion the animals tolerated the pharmaceutical formulation up to the 
highest dose tested. Microscopic examinations were done in 2 male and 2 female dogs in the control 
group, in 1 male and 1 female dogs in the group I, in 1 male and 1 female dog in the group II and in 2 
male and 2 female dogs in the group III. The only adverse effects reported were salivation and 
occasional vomiting. It is reported that one high dose female lost weight during the first week of 
treatment but recovered and that one high dose male exhibited a slight anaemia terminally. Since 
apparently these symptoms were mild or cleared before the end of the study, the authors considered 
that the formulation was non toxic to dogs under the conditions of the study. It is observed however by 
the CEF Panel that only one or two animals per sex were subjected to examination in the high dose 
group formulation. The relevance of these findings for the evaluation of the safety of CPC is 
questionable, given that it was administered as a mixture with another compound. The same report 
describes a study done on groups of 20 Sprague-Dawley rats of both sexes administered the same 
doses of the pharmaceutical formulation Cepacol® as in the previous study with dogs for 30 days 
(Scientific Laboratories, 1969b).  Some rats exhibited signs of mild respiratory disease during the 
study. All other effects appeared to be incidental, except for deaths which were numerous in the high 
dose group but attributed to the intubation protocol, the drug concentrations (without details) as well 
as dosage volume. Food consumption and body weight gains were not reported affected. Clinical 
laboratory and urine examinations were reported as not showing effects. Gross necropsy findings 
(such as organ weight determinations) and microscopic examinations were reported as not showing 
effects related to the treatment. The authors considered that the formulation was non toxic to rats 
under the conditions of the study. The relevance of these findings for the evaluation of the safety of 
CPC is questionable, given that it was administered as a mixture with another compound. 
Another subchronic toxicity study was done in groups of male and female beagle dogs, administered 
during 30 days a pharmaceutical formulation containing dextromethorphane HBr (5.0 mg), 
doxylamine succinate (32.0 mg), CPC (1:1500), benzyl alcohol (0.3 %), menthol (1.1 mg), horchound 
flavour compound (9.16 mg), glycerin (22 mg) and sucrose, glucose, C. Yellow No.5, Blue No. 1 and 
Red No. 2 (Cepa-Tuss Teoches) (Scientific Laboratories, 1965). Twelve animals were divided in four 
groups dosed with 0 (4 dogs, 2 males & 2 females), 1 (2 dogs, 1 male & 1 female), 3 (2 dogs, 1 male 
& 1 female) and 10 (4 dogs, 2 males & 2 females) ml/kg bw/day of the formulation. No particular 
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effect related to the treatment was reported. Occasional vomiting in the high dose group and some 
increased salivation of all treated animals was noticed. Slight reductions in haemoglobin, hematocrit 
and erythrocyte counts were reported in the high dose group, but overall haematology parameters were 
either within normal ranges or were explained by reactions to parasite infections. Biological chemistry 
and urinalysis were normal. Gross necropsy and microscopic findings were reported as not related to 
the treatment. For example, mild to moderate pulmonary granulomatosous pneumonia and granulomas 
in liver were attributed to a rare nematode parasites infection (Filarioides milksi), whether focal 
cyatitis in the urinary bladder was related to catheterisation manipulation. The authors concluded that 
dogs tolerated well 10 ml/kg bw/day or less of the pharmaceutical formulation.  
The same report describes a study done in four groups of 20 Wistar-Morini albino rats (10 per  sexes), 
administered during 30 days a pharmaceutical formulation containing benzocaine 0.2 mg, dibucaine 
0.03 mg and CPC 0.05 mg for 18 days (Scientific Laboratories, 1965). Groups were dosed with 0, 1, 3 
and 10 ml/kg bw/day of the formulation. Almost all animals in the high dose group died during the 
first 8 days of treatment, at the time the animals were being intubated. The increased mortality was 
attributed to the greater dose volume of formulation and concentration of the compound and thus 
dosage was reduced for all groups afterwards. A few rats showed signs of mild respiratory 
dysfunction. No changes in food consumption and body weights were reported. Haematology, 
biological chemistry and urinary parameters were reported as normal. Gross necropsy and microscopic 
findings were reported as not related to the treatment (for example sporadic liver and lungs abscess, 
oedemas, lymphoid infiltrations, haemorrhages). Organ weights were not changed. The authors 
concluded that rats tolerated well 10 ml/kg bw/day or less of the pharmaceutical formulation.  
The relevance of these studies for the evaluation of the safety of CPC is questionable, given that it was 
administered as a mixture with another compound. 
In a more recent 13-week study, groups of 20 Sprague-Dawley albino rats of both sexes were 
administered 0, 125, 250, 500, and 1000 ppm of CPC orally in the diet, corresponding to an average 
consumption of approximately 0, 9, 18, 35 and 70 mg CPC/kg bw/day for males, and to 0, 11, 22, 42 
and 84 mg CPC/kg bw/day for females, respectively (Charles River Laboratories, 2006a). The study 
was done under GLP conditions according to international guidelines. Regular observations included 
clinical parameters, body weights and feed consumptions, ophthalmology and neurological 
examinations such as functional observation tests performed on all animals (passive home cage, 
interactive cage behaviour, response to handling, etc); no open field assessments were performed. 
Further observations included haematology and coagulation parameters, serum chemistry, urinalysis, 
organ weights, histopathology on all tissues from all animals in groups 0 and 1000 ppm, in all early 
death animals and on all gross lesions. There was only one death during the study, which was not 
considered by the authors to be related to the treatment (carditis). In males and females, from the 1000 
ppm group, mean body weights were significantly lower than in controls and were related to decreased 
feed consumption. No ophthalmological abnormalities were reported. Neurological examinations did 
not show changes related to the treatment. Haematological examination showed statistically significant 
increases in haematocrit values in females from the 1000 ppm group, whereas mean corpuscular 
haemoglobin concentration in those animals was decreased consistently but did not reach statistical 
significance at the end of the study. Red blood cell counts were consistently increased in females from 
the 1000 ppm group throughout the study and were considered treatment related by the authors. 
However since males did not show changes they were considered by the authors as not biologically 
significant or adverse. No other significant change in haematology parameters was reported. Serum 
chemistry showed significant lower levels of alkaline phosphatase and creatinine levels in males from 
the 1000 ppm groups. In females creatinine levels were also significantly decreased in the 1000 ppm 
group. The authors considered this effect as treatment related but not to be biologically significant or 
adverse since there were no similar changes in females. No other significant change was reported in 
serum chemistry. Urinalysis did not report treatment related changes. In males caecum weights 
relative to body weight in the 500 and 1000 ppm groups were statistically significantly increased. 
Weights of brain, heart and testis, relative to body weight, were also statistically increased in males 
from the 1000 ppm group. In females weights of adrenals glands, brain, caecum, heart, kidney, liver, 
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lung, ovary and spleen, relative to body weight, were significantly increased in the 1000 ppm group. 
The authors did not considered them to be adverse because they were not associated with any other 
effects (not precisely identified) or with histopathological lesions. According to the CEF Panel, taking 
into account the increase in caecum weights in males in the 500 ppm group, a No-Observable-
Adverse-Effect-Level (NOAEL) of 250 ppm (18 mg/kg bw/day) can be identified. 
In a 28-day study, groups of one female and one male Beagle dogs were administered 0, 250, 500, 
1000, and 1500 ppm of CPC orally in the diet, corresponding to an average consumption of 
approximately 0, 8, 8, 16 and 20 mg CPC/kg bw/day for males, and to 0, 7, 11, 15 and 11 mg CPC/kg 
bw/day for females, respectively (Charles River Laboratories, 2006b). Observations performed 
included clinical observations, body weights and feed consumptions, haematology and coagulation 
parameters, clinical chemistry, urinalysis, organ weights and histopathology. In both sexes 
administration of 1500 ppm CPC resulted in abnormal stool (soft or watery). In this dose group animal 
body weights and feed consumption decreased significantly throughout the study duration. Due to 
these effects, the average consumption of CPC by animals in the 1500 ppm group, more pronounced in 
females, was comparable to the animals allocated to the 500 ppm group. In males the average 
consumption of CPC did not differ amongst animals allocated to the 1000 and 1500 ppm groups or 
amongst animals allocated to the 250 and 500 ppm groups. These findings suggest that a full dose-
dependent exposure could not be achieved in this study. No haematological or coagulation changes 
related to the treatment were reported. Alanine aminotransferase activity was increased in males from 
the 250 and 1000 ppm group and females showed an increased dose-dependent trend in ALT activity 
from the 250 ppm group onwards. These changes were considered as not adverse by the authors since 
no histopathological lesions in the liver were associated with this change. No changes in urinalysis 
parameters and organ weights were reported. Upon histopathology examination, bilateral vacuolation 
of the tubular epithelial cells of the straight collecting ducts in the medullar rays was reported in 
females from the 1500 ppm group. The vacuolated cells contained multiple clear cytoplasm vacuoles 
varying in size from 2 to 8 microns in diameter approximately. Male animals in the same dose group 
did not show these lesions nor did the animals, females and males, from the other dose groups. The 
authors considered the vacuolisation effect in females as an incidental background finding based on 
the absence of a similar finding in males from the same group and in the animals from the 250 ppm 
group The CEF Panel considered however that no conclusions can be drawn from this study since as a 
result of treatment with CPC feed intake was strongly diminished, not allowing establishment of a 
dose-response. Furthermore, the number of animals was insufficient to allow characterisation of the 
observed effects. 
In a 90-day study, groups of four Beagle dogs of both sexes were administered 0, 250, 375 and 
1000/500 ppm of CPC orally in the diet, corresponding to an average consumption of approximately 0, 
8, 12, 14 and 17 mg CPC/kg bw/day for males, and to 0, 8, 11, 17 and 17 mg CPC/kg bw/day for 
females, respectively (Charles River Laboratories, 2006c). Observations performed included clinical 
observations, physical examinations body weights and feed consumptions, ophthalmic examinations, 
cardiology evaluations, neurological examinations (home cage behaviour, out of cage behaviour, 
reflex activity, and postural reactions). Further observations included haematology and coagulation 
parameters, serum chemistry, urinalysis, organ weights and histopathology on control animals and 
animals from the 1000 ppm group. Body weight gains and feed consumption decreased in male 
animals from the 375, 500 and 1000 ppm groups as compared to controls. Thin body conditions were 
observed in one male in each group starting at a dose of 375 and onwards and in females from the 
100/500 ppm group. Because of these effects in male animals from the 1000 ppm group administration 
of CPC was stopped from study day 29 to study days 42/41 (males/females). After this period dosing 
with CPC at 500 ppm was continued until the end of the study. Body weights were no longer 
statistically significant different from the controls at this dose. No effect on body weights were 
reported in female animals. Across all groups administration of CPC resulted in abnormal stools (soft, 
watery or mucoid aspect) in both sexes. The average amount of CPC consumed by males and females 
animals from the 500 and 1000 ppm doses were similar (14 vs. 17 mg/kg bw/day and 17 vs. 17 mg/kg 
bw/day, respectively). No physical, ophthalmology or neurological changes related to the treatment 
were reported. Upon cardiology evaluations no differences were noted for heart rate, RR interval, PR 
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interval, QRS duration, QT interval or QTc, except on study day 86. On study day 86 RR interval was 
statistically significant longer in males from the 375 ppm group and in females from the 375, 500 and 
1000 ppm groups as compared to controls. The mean RR interval differences ranged from 14 to 22 
milliseconds. These changes were not considered toxicologically significant by the authors. 
Haematological examination showed dose-dependent significant decreases in red blood cell counts, 
haemoglobin and haematocrit concentrations of male animals. Platelet counts were also decreased in 
males across all treated groups although not reaching statistical significance. Activated partial 
thrombin time was significantly decreased in females from almost all treated groups and reticulocyte 
levels were consistently increased in those animals. Haemoglobin levels and hematocrit values were 
significantly decreased in females from the 1000 ppm group. Monocytes were decreased in females 
from the 375, 500 and 1000 ppm groups. Some of the changes were considered by the authors as 
incidental and not related to CPC administration because they were not dose-dependent, were gender 
specific and inversely related. The presence of reticulocytes however was considered by the authors as 
suggesting a dose-dependent regenerative anaemia, most likely related to decreased feed consumption. 
The CEF Panel considered that taken together the haematology findings reported in male and female 
animals starting from the 375 ppm group suggest a treatment related effect on the blood homeostasis 
which is directly or indirectly related to CPC treatment. Cholesterol levels in males from the 250 ppm 
and onward groups were decreased although changes became significant at different study days. Other 
changes on urea nitrogen, aspartate aminotransferase, sorbitol dehydrogenase, creatinine and inorganic 
phosphorus were also reported in those animals. There were no changes reported as treatment related 
in the urinalysis parameters measured. No abnormal organ weights were reported in females. In males 
from the 375 ppm group and onwards reduced absolute or relative weights on epididymis, livers and 
thymus were reported. The authors considered these changes as not dose-dependent, and not supported 
by histopathology findings and thus they were not treatment related. Upon histopathology examination 
none of the few findings reported were considered by the authors as related to CPC administration 
(infiltration of mononuclear cells in the brain, haemorrhage and neutrophilic infiltration in the rectum, 
hyperplasia and haemorrhage of the lymph nodes, cysts presence in some animals, etc). However, the 
CEF Panel noted that the average amount of CPC consumed by males and females animals from the 
500 and 1000 ppm doses was similar and thus a dose-dependency of effect on these two groups cannot 
be expected. Furthermore, the CEF Panel noted that the lack of histopathology findings to discard the 
relevance of the reduced weights of some organs identified in this study cannot be argued since 
histopathological examinations were only performed on animals from the control and the 1000 ppm 
groups. Taking into account the lack of full dose-response and the palatability issue, the CEF Panel 
considered that,  the study was not suitable for the derivation of a NOAEL. In summary, the CEF 
Panel had access to information on subchronic toxicity studies on CPC. The most recent information 
submitted by the applicant consisted of a 14-day palatability study, a 28-day and a 90-day toxicity 
studies in Sprague-Dawley rats, as well as a 28-day and a 90-day toxicity studies in Beagle dogs. 
Other available subchronic studies were either insufficiently described or tested mixtures of CPC with 
other compounds, which did not allow clear conclusions on the safety of CPC to be drawn. 
From the more recent 90-day toxicity study in Sprague-Dawley rats, the CEF Panel could identify a 
NOAEL of 18 mg/kg bw/day in rats, based on increased caecum weights noted in males. The CEF 
Panel considered the increase in caecum weight as relevant for risk characterisation of Cecure®. An 
increase in caecum to body weight ratios has been consistently positively correlated with increased 
dietary levels of CPC in sub-chronic rat studies (Redfield Laboratories, 2001b; Procter & Gamble, 
1979; USAEH-HT, 1969; BIBRA, 1988; Charles River Laboratories, 2006a). Furthermore, in one of 
these studies it was noted that as the concentration of CPC chloride increased, the total number of 
microorganisms in the caecal contents decreased in both sexes (USAEH-HT, 1969). An increase in 
caecum weight in animals has also been associated elsewhere with modification on the composition of 
the intestinal microbiota (Licht et al., 2006) and therefore the CEF Panel considered that the 
possibility of a potential similar effect of CPC occurring in the gastrointestinal microflora of humans 
should not be disregarded. 
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2.1.3.3 Chronic toxicity and carcinogenicity 
No studies specifically done with Cecure® were available to the CEF Panel addressing this parameter. 
Two chronic toxicity studies of 6 months and 1 year in which doses from 5 to 75 mg/kg bw/day of 
CPC were administered by gavage to animals (species not described) were reported (Genco, 1995). 
Significant decreases in body weight and body weight gain at doses of 40 and 75 mg/kg bw/day were 
reported in animals of both sexes and in some animals at 15 mg/kg bw/day dosage. At necropsy, 
gastrointestinal irritation was observed, manifested as thickening of the stomach mucosa. 
BIBRA summarised a carcinogenicity  study done on rats with CPC (BIBRA, 1988) as follows: 
Groups of 10 rats of both sexes (species not identified) were administered CPC incorporated in a 
vinyl-copolymer (no more details) at dietary levels providing 7 or 35 mg/kg bw/day of CPC in the diet 
for one year. No clinical effects (unspecified) or blood changes were not reported nor were there any 
microscopic abnormalities in the major tissues analysed (unspecified). BIBRA mentions the limited 
utility of this study to assess carcinogenicity given the small number of animals and tissues examined. 
2.1.3.4 Reproductive and developmental toxicity  
No studies specifically done with Cecure® or CPC were available to the CEF Panel addressing this 
parameter.  
BIBRA describes a reproductive/developmental toxicity study done on rats (strains not identified) fed 
CPC incorporated in a vinyl-copolymer (no more details), as follows: 
Groups of 4 female rats (strain not described) were fed 7 or 35 mg/kg bw/day CPC for 3 months prior 
to mating and throughout pregnancy and lactation (BIBRA, 1988). At weaning, offspring were given 
the same diet as their mothers for 3 months prior to mating and throughout pregnancy and lactation. 
Third-generation offspring were again fed the CPC diet and mated after 3 months. Fertility and the 
incidence of malformations were within normal limits in each generation. 
Groups of 15 pregnant New Zealand SPF rabbits were gavaged with 0, 2.5, 12.0, or 100 mg/kg bw 
CPC containing 1/9 domiphen bromide (0, 0.28, 1.33, and 11.08 mg/kg bw respectively), from day 7 
to day 18 of gestation (Procter & Gamble, 1979). Most of the dams in the 100 mg/kg bw/day group 
died. The authors decided to create two new groups in which the six remaining untreated dams for 
each of the two high-dose groups were given CPC at 25 mg/kg bw or a combination of 25 mg/kg bw 
CPC and 2.8 mg/kg bw domiphen bromide daily from day 7 to day 18 of gestation. Two more dams 
from the 12.0 mg/kg bw/day and 25 mg/kg bw/day CPC died at the end of the study. Necropsy 
examination of these dams revealed severe irritation of the gastrointestinal tract, accompanied by 
diarrhoea and gastric ulceration. Weight losses were reported in animals from the new two groups 
associated with observed anorexia. There were aborted foetuses in the 2.5 mg/kg bw/day (one), 12.0 
mg/kg bw/day (two), and 25 mg/kg bw CPC and 2.8 mg/kg bw domiphen bromide (two) groups. The 
foetus losses were associated with maternal toxicity which included (no more details) anorexia and 
weight loss. No differences were reported by the authors in the average numbers of corpora lutea or 
resorptions, but the high dose group (25 mg/kg bw/day) without domiphen bromide showed a higher 
incidence of resorptions associated by the authors to the maternal toxicity. Also differences in the 
number of implants were reported in the 25 mg/kg bw/day group and from the high-dose group 
containing domiphen bromide, but they were considered by the authors as not treatment-related since 
exposure occurred after implantation. In the dams of these two groups there were also reduced 
numbers of live foetuses reported but they were associated with maternal toxicity. Female foetal 
weights were significantly lower than controls in the high-dose CPC group. No differences were 
reported in the average numbers of foetuses of both sexes in the remaining lower concentration 
groups, nor were there reported differences in the foetal soft tissue or skeletal abnormalities. The 
authors conclude that the test materials were increasingly toxic to the dams and indirectly to the 
embryos or foetuses as the doses were increased, but none of the toxic effects were considered 
developmental. The dose of 25 mg/kg bw/day was considered by the authors as a non-effect dose for 
developmental effects. 
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Several deviations and adjustments in this study to compensate for the initial death rates at the highest 
dose administered and the high rate of maternal toxicity reported do not allow valid conclusions from 
this study to be drawn with respect to reproductive toxicity. Furthermore, the relevance of this 
publication to evaluate the safety of CPC is questionable, given that it was administered as a mixture 
with another compound. 
2.1.3.5 Genotoxicity  
Information on Cecure® genotoxicity is provided in two unpublished studies submitted by the 
applicant. In these studies Cecure® solution, as described in paragraph 1.1, was evaluated for the 
induction of reverse mutations in bacteria and chromosomal aberrations in cultured mammalian cells. 
Both studies were performed in compliance with Good Laboratory Practice, following the most recent 
OECD Test Guidelines. 
In the bacterial reversion assay (Next Century Inc., 2002), Cecure® solution  was tested in the 
Salmonella typhimurium strains TA1535, TA97a, TA98, TA100 and with Escherichia coli WP2 uvrA 
pKM101 in a plate incorporation assay, with and without metabolic activation by Aroclor-induced rat 
liver S9 at the following concentrations: 5, 10, 50, 100, 500, 1000, 2500 and 5000 g Cecure®/plate 
(equivalent respectively to 0.05, 0.1, 0.5, 1, 5, 25, 50 g CPC/plate). Deionised water was used as 
solvent. Based on the toxicity observed in the first trial, in the repeat test the following concentrations 
were evaluated: 5, 10, 50, 100 and 500 g Cecure®/plate (equivalent respectively to 0.05, 0.1, 0.5, 1 
and 5 g CPC/plate) without S9; 100, 500, 1000, 2500, 5000 g Cecure®/plate (equivalent 
respectively to 1, 5, 10, 25 and 50 g CPC/plate) with S9. In both trials, all concentrations were tested 
in triplicate. Treatment with Cecure® was toxic in the absence of S9 at concentrations  1000 g 
Cecure®/plate (equivalent to 10 g CPC/plate). No treatment related increase of revertant colonies 
was observed with or without S9 in any tester strain.  
The cytogenetic assay was performed with Chinese hamster ovary cells (CHO-K1) (Next Century Inc., 
2001). Cecure® was tested for clastogenicity using duplicate cultures and scoring structural 
chromosomal aberrations in one hundred metaphases per culture. The following dose levels were 
selected for microscopic analysis: 100, 500 and 1000 g /ml (equivalent to 1, 5 and 10 g CPC/ml) in 
the first experiment with 3 h treatment  S9 and harvest at 20 h; 50, 100 and 250 g/ml (equivalent to 
0.5, 1 and 2.5 g CPC/ml) in the second experiment with continuous (20 h) treatment without S9, and 
250, 500 and 1000 g/ml (equivalent to 2.5, 5 and 10 g CPC/ml) in the repeat test with S9. Higher 
doses resulted in excessive toxicity, assessed as percent confluence. In both experiments, treatment 
with Cecure® did not increase the frequency of aberrant cells or structural chromosomal aberrations. 
No increase in polyploid cells was observed either. 
Supplementary information on the genotoxicity of CPC is provided by the following published 
studies: 
In a screening of pharmaceutical drugs, negative results were obtained with a CPC preparation 
(Cepacol) in tests for mitotic non-disjunction and crossing-over in Aspergillus nidulans (Bignami et 
al., 1974). No further details are given. 
Negative results with Cepacol were reported in a screening of 140 health-related agents in the 
Tradescantia-micronucleus assay. The test material was applied by liquid absorption through the stem 
at the dose of 0.5 – 1 tablet (Ma et al., 1984). No further details are available from this study.  
Negative results were also obtained with a xerox reprographic toner containing 2 % of CPC in the 
following battery of genotoxicity tests: i) bacterial reversion (Ames) test with Salmonella typhimurium 
TA1535, TA1537, TA1538, TA98, TA100 (from 0.5 to 1,000 g toner/plate, with and without S9); ii), 
mouse lymphoma forward mutation test at the tk locus (from 31.1 to 400 g toner/ml, with and 
without S9); iii) sister chromatid exchanges in CHO cells (from 0.16 to 100 g toner/ml, with and 
without S9); iv) micronucleus in bone marrow of rats (10 males and 9 females) exposed by inhalation 
to the toner dust at 1343 mg/m3 6h/day, 5 days/week for 13 weeks (Lin, 1999).  
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The Cepacol® mouthwash (0.05% CPC ) tested positive in the Drosophila Wing-spot test, where 
increased mitotic recombination was observed in larvae feed with dry medium rehydrated with 75% 
and 100% Cepacol®. However, this result was attributed to the ethanol content in the mouthwash 
(16.8%), as pure CPC at the same concentration present in the mouthwash produced negative results 
(Rodriguez et al., 2007)  
No relevant information is provided by the other published studies submitted by the applicant: in the 
study by Yamaguchi and Yamashita (1979) the effects of various detergents, including CPC, on the 
mutagenicity of autoxidised linoleic acid was evaluated in the Salmonella typhimurium reversion test. 
However, no data on CPC alone are presented. In the study by Smith and Lofty (1955), aberrant 
anaphase divisions, which are of questionable relevance for mammalian cells, were observed in 
meristems of Vicia faba grown in presence of CPC (0.001 – 0.02%). 
2.1.3.6 Allergenicity, hypersensitivity and intolerance 
No information on oral allergenicity was available. Skin irritation test in animals and humans have 
demonstrated that CPC is an irritant compound (Watanabe et al, 2002), also when inhaled.   
2.2. Conclusions on toxicological studies 
The available data indicate that CPC, tested as a working diluted solution in Cecure®, is not 
mutagenic in bacteria and not clastogenic in cultured mammalian cells. Negative results were also 
obtained in a gene mutation assay with CPC in mouse lymphoma cells and in limited tests in 
Aspergillus, Tradescantia and Drosophila. The CEF Panel noted that relatively low doses of the active 
component CPC were applied in the genotoxicity studies carried out on Cecure® solution; on the other 
hand, given the toxicity elicited by the test material, which can reasonably be attributed to the CPC 
content, testing of higher doses was not feasible. The CEF Panel also noted that the highest toxicity of 
the test material was elicited in the bacterial assay (without S9), as expected in view of the 
antimicrobial properties of CPC. Whilst this fact may to some extent limit the relevance of the 
bacterial assay for the assessment of the mutagenic potential of CPC, supporting information regarding 
this end-point are provided by the negative results in the mouse lymphoma assay reported in the study 
by Lin (1999). The Panel also noted that in addition to these consistently negative results the substance 
does not contain structural alerts for genotoxicity. Thus, based on the available evidence, the CEF 
Panel considered that there is no concern for genotoxicity. 
The CEF Panel was not able to derive a toxicological reference value for CPC on the basis of the data 
provided by the applicant. There were no data on long term studies available nor were data available 
on reproductive and developmental toxicity on CPC. The only combined reproductive and 
developmental study with CPC for this evaluation was a rat study for which the data available to the 
CEF Panel was a summary reporting no effects on fertility or malformation of offspring up to the third 
generation. Other long term or repro/developmental toxicity studies available were either insufficiently 
described or tested CPC in combination with other compounds, although they showed negative results 
overall. The CEF Panel noted however that none of the findings reported on reproductive organs in 
sub-chronic toxicity studies were related to the treatment with CPC.   
However, based on the data provided by the applicant the CEF Panel could establish a point of 
departure to assess the safety of Cecure® based on the NOAEL of 18 mg/kg bw/day derived from the 
13-week toxicity study in Sprague-Dawley rats, in which an increase in caecum weights in male rats 
was observed. The CEF Panel considered the increase in caecum weight as relevant for risk 
characterisation of Cecure®. An increase in caecum to body weight ratios has been consistently 
positively correlated with increased dietary levels of CPC in sub-chronic rat studies (Redfield 
Laboratories, 2001b; Procter & Gamble, 1979; USAEH-HT, 1969; BIBRA, 1988; Charles River 
Laboratories, 2006a). Furthermore, in one of these studies it was noted that as the concentration of 
CPC increased, the total number of microorganisms in the caecal contents decreased in both sexes 
(USAEH-HT, 1969).  An increase in caecum weight in animals has also been associated elsewhere 
with modification on the composition of the intestinal microbiota (Licht et al., 2006) and therefore, the 
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CEF Panel considered that the possibility of a potential similar effect of CPC occurring in the 
gastrointestinal microflora of humans should not be disregarded. 
Taking into account the highest calculated potential exposure to CPC of up to 5.7 µg/kg bw/day at the 
mean and 17. 8 µg/kg bw/day at the 95th percentile of treated poultry consumption, the conservative 
margins of safety would be more than 3000 at the mean and more than 1000 at the 95th percentile, 
respectively, when compared to the NOAEL of 18 mg/kg bw/day identified by the CEF Panel in a 13-
week toxicity study in Sprague-Dawley rats. The CEF Panel noted that these exposure estimates are 
worst cases since they assumed that all poultry carcasses, which are going to be consumed, have been 
treated with Cecure®. Concerning PG exposure arising from the use of Cecure® as processing aids, 
worst case exposure estimations are 0.5 µg/kg bw/day at the mean and 1.4 µg/kg bw/day at the 95th 
percentile. This estimated daily intake of PG is more than 22000 and 7000 times, respectively, below 
the Acceptable Daily Intake (ADI) of 0 - 10 mg/kg bw/day allocated by the Joint FAO/WHO Expert 
Committee on Food Additives (JECFA) (WHO Technical report series No. 14, 1980) and 3500 times 
below the TDI of 5 mg/kg bw/day established by the Scientific Committee on Food (SCF) for PG. 
Therefore, based on the toxicological data available, the estimated margins of safety (going from three 
orders of magnitude for CPC to four orders of magnitude for PG) and the conservative exposure 
estimates used to assess CPC exposure from consumption of poultry carcasses, the CEF Panel 
considers that there are no safety concerns for humans from the proposed use of Cecure® for removal 
of microbial surface contamination from raw poultry under the usage conditions specified in this 
opinion. The Panel was not able to assess total exposure of CPC from other potential dietary sources 
and non dietary sources.  
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3. The efficacy, i.e. does the use of the formulated product significantly reduce the level of 
contamination of pathogenic microorganisms 
3.1. Introduction 
According to the EFSA guidance document (EFSA, 2010), the use of substance(s) as decontaminating 
treatments will be regarded efficacious when any reduction of the prevalence and/or numbers of 
pathogenic target microorganisms is statistically significant as compared to the control (e.g. water) 
and, at the same time, this reduction has a positive impact on reduction of human illness cases (EFSA, 
2010). Risk assessment studies on pathogenic microbial species (EFSA, 2011a, 2011b) have shown 
that mean reductions in microbial counts by even a 0.5 log10 unit may reduce consumer risks to a 
significant extent. In addition, the data show that there is a linear correlation between reductions in 
prevalence and reductions of consumer risks. Efficacy depends on a range of factors such as 
concentration of the decontaminating agent, contact time, temperature, mode of application, the 
microbial load of the surface, and other conditions of application. 
3.2. Selection of studies for evaluation  
As indicated, use of potable water solutions of Cecure®, containing < 1% CPC, the active ingredient, 
in combination with food-grade polypropylene glycol, was petitioned for approval as a decontaminant 
treatment in raw poultry meat. The process and results of the evaluation by the BIOHAZ Panel of the 
studies included in the dossier for the efficacy of Cecure® as a decontamination agent for raw poultry 
meat are as follows: 
3.2.1. Criteria used by the BIOHAZ Panel for inclusion or exclusion of submitted studies 
The following criteria were used by the BIOHAZ Panel in the selection of studies to be used in the 
evaluation of decontamination efficacy by Cecure®: 
o The studies selected for evaluation should involve application on broiler carcasses, chicken 
skin, or skin-on chicken parts.  
o The evaluation of the efficacy should focus on Cecure® treated samples versus water washed 
samples, or versus untreated controls. 
o Target microbial groups to be considered are those listed in the petition by the applicant, 
which included “Salmonella, Campylobacter, Listeria, Staphylococcus aureus, Escherichia 
coli (including O157:H7), Pseudomonas, total coliforms, viruses, and other naturally 
occurring microorganisms on raw poultry carcasses.”  
3.2.2. Determination of the strength of evidence of selected for evaluation studies 
The body of evidence selected (see below) from the studies submitted in the dossier was evaluated by 
the EFSA BIOHAZ Panel, taking into account whether the studies were done in the laboratory, in a 
slaughterhouse (industrial scale) or under pilot plant conditions, and whether they used inoculated or 
naturally contaminated poultry samples. Table 1 summarizes the weight given to the data from 
naturally contaminated versus inoculated samples and industrial-scale versus pilot-scale versus 
laboratory-scale studies. These criteria were used in two previous EFSA Opinions (EFSA, 2011b, 
2011c) and were developed in the FAO/WHO report on Benefits and Risks of the Use of Chlorine-
containing Disinfectants in Food Production and Food Processing (FAO/WHO, 2008). The results of 
this evaluation are shown in Tables 2 and 3. 
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Table 1:  Relative strength of the contribution of study data to the general body of evidence, based 
on study type 
Study type Natural contamination Inoculated studies 
Industrial  High  Not applicable  
Pilot-scalea Highb/medium  Mediumc  
Laboratory  Mediumc  Lowd  
a  Experiments using industrial equipment in non-industrial settings. 
b If the pilot process is representative of the industrial process; otherwise, evidence makes a “medium” contribution to the 
body of evidence. 
c Data would not be sufficient to inform a quantitative microbial risk assessment or to allow definitive conclusions on risk 
reduction. 
d Data are indicative of a disinfectant effect that may be reproducible in practice, but individually do not allow definitive 
conclusions on risk reduction. 
 
3.3. Results of the selection of studies for evaluation 
o The application dossier included 15 peer reviewed published papers dealing with testing of CPC 
or Cecure® for decontamination (Table 2). Of the 15 peer reviewed papers submitted by the 
applicant for consideration; five were selected for consideration in evaluating the efficacy of CPC 
or Cecure® in poultry meat decontamination. Four papers were excluded because they did not 
evaluate poultry meat, two did not test CPC nor Cecure®, two used chicken skin as a model to 
evaluate bacterial attachment effects, one determined minimum inhibitory concentrations (MIC), 
one evaluated boneless/skinless poultry meat (whereas the application is for skin-on products), 
and one is a review of published literature with no additional data. Therefore, the peer-reviewed 
published papers selected and evaluated included two industrial, one pilot, and two laboratory 
level studies.  
o Of the included peer reviewed studies, two were of high strength of evidence, one of medium 
strength and two of low strength of evidence (Table 2). 
o The applicant also included in the application dossier 13 reports with data of in-house studies in 
support of the application for approval of Cecure® for use in the decontamination of fresh poultry 
products (Table 3). All, but two of these studies were considered in the evaluation of the efficacy 
of Cecure® against microbial contamination on fresh poultry; rejection of the two papers was 
based on the fact that contamination levels in controls were too low to allow quantification of 
decontaminating effects. One of the studies (No. 100901) considered potential sub-lethal injury of 
microorganisms due to treatment with the decontamination agent as it evaluated counts of 
inoculated microorganisms on thighs immediately after treatment and after 7 days of refrigerated 
storage. 
o Eight of the in-house studies considered by the BIOHAZ Panel were conducted on broiler 
carcasses (Table 3) with natural contamination (except for study No. 060607 which involved 
inoculation with E. coli isolated from a carcass rinse, and study No. 060613 which involved 
inoculation with 6 log10 units of Salmonella and E. coli). Seven of the studies (Nos. 060302, 
060401, 060407, 060510, 061010, 070414, and Waldroup et al., 1999) were of industrial scale, 
and three of pilot scale (Nos. 060607 and 060613, and Waldroup, 2000a); three studies were 
conducted on carcasses pre-chill (Nos. 061010, 070414, and Waldroup et al., 2000a), six on post-
chill carcasses (Nos. 060407, 060510, 060607, 060613, 100901, and Waldroup et al., 1999), and 
two on pre- and post-chill carcasses (Nos. 060302 and 060401). For the studies reporting it, 
treatment temperature was at 21°-35°C. Treatment application involved: drenching in studies No. 
060302, No. 060401, No. 060407, No. 060510, No. 060607, No. 060613, No. 0 61010, and No. 
070414; spraying in studies Waldroup et al. (1999; 2000b); and, misting and dipping in Waldroup 
et al. (2000a). The antimicrobial was removed or rinsed in all studies, except for Waldroup et al.  
(1999), which involved 3 min dripping after treatment, and sampling by whole carcass rinsing.  
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o Seven of the in-house studies were classified as of high strength of evidence (Nos. 060401, 
060407, 060302, 060510, 061010, 070414, and Waldroup et al., 1999), one of high/medium 
(Waldroup et al., 2000a), two of medium (Nos. 060607, 060613), and one of low strength of 
evidence (No. 100901) (Table 3). 
o Studies evaluating the active ingredient (CPC) as well as the formulated product/preparation 
(Cecure®) were considered in the evaluation. The active ingredient, CPC, instead of the 
preparation, Cecure®, was tested in the published studies by Breen et al. (1997), Arritt et al. 
(2002) and Li et al. (1997), and in the in-house studies at Plant-1 by Waldroup et al. (1999) and 
by (Waldroup et al., 2000a); the plant-2 study of (Waldroup et al., 1999), and all other in-house 
studies evaluated Cecure®. In these studies it was not always clear whether the concentrations 
reported were for CPC or Cecure®.  
o The studies submitted by the applicant and selected for evaluation by the BIOHAZ Panel 
included data for the following microorganisms: Salmonella enterica serovars, Campylobacter 
spp., E. coli (specific data on serotype O157:H7 were not included in the studies evaluated), 
Pseudomonas, and total coliforms, while most studies also evaluated changes in aerobic plate 
counts (APC).  
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Table 2:  Peer reviewed papers submitted by the applicant and the reasons for exclusion/inclusion from the assessment  
Reference Inclusion in the 
assessment 
Reason for exclusion  Industrial 
/pilot/ lab 
Natural 
/inoculated 
Microorganisms Product group Strength of 
evidence 
Baker et al. (2010) YES  Industrial Natural APC
9
 Broiler carcass High 
Beers et al. (2006) YES  Industrial Natural APC, E. coli, Coliforms, 
Salmonella, Campylobacter 
Broiler carcass High 
Bereswill et al. (1999) NO Determined MIC      
Breen et al. (1995) NO Bacterial attachment to 
chicken skin and MIC 
     
Breen et al. (1997) YES*  Lab Inoculated  Salmonella Typhimurium Chicken skin Low 
Arritt et al. (2002) YES**  Lab Inoculated Campylobacter Chicken skin Low 
Pohlman et al. (2002) NO Not about poultry      
Singh et al. (2005a)  NO  Not about poultry      
Singh et al. (2005b)  NO Not about poultry      
Singh et al. (2005c)  NO Not about poultry      
Slavik et al. (1995) NO Not about CPC      
Waldroup et al. (2010) NO Review of previous results       
Bai et al. (2007) NO Boneless / skinless meat      
Li et al. (1997) YES  Pilot Inoculated Salmonella Typhimurium Broiler carcass Medium 
Waldroup, 1992 NO Not about CPC      
*on irradiated skin    **skin model  
                                                     
9  Although the application of the formulated product is intended to reduce the prevalence and/or numbers of target pathogenic microorganisms, data on the counts of non-pathogenic 
microorganisms, such as indicator microorganisms and total viable counts, should be provided and may also assist in the assessment of the overall efficacy of the proposed application. 
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Table 3:  In-house studies submitted by the applicant and the reasons for exclusion/inclusion from the assessment  
Reference Inclusion in 
assessment 
Reason for exclusion Industrial 
/pilot/lab 
Natural/ 
inoculated 
Product group Microorganisms Strength of 
evidence 
No. 060302 YES  Industrial Natural Broiler carcasses APC, Coliforms, E. coli High 
No. 060401 YES  Industrial Natural Broiler carcasses APC, Salmonella, E. coli High 
No. 060407 YES  Industrial Natural Broiler carcasses APC, Coliforms, E. coli High 
No. 060510 YES  Industrial Natural Broiler carcasses APC
10
 High 
No. 060607 YES  Pilot Inoculated Broiler carcasses APC, Coliforms, E. coli Medium 
No. 060613 YES  Pilot Inoculated Broiler carcasses APC, Salmonella, E. coli Medium 
No. 061010 YES  Industrial Natural Broiler carcasses APC, Enterobacteriaceae, Pseudomonas, 
Coliforms, E. coli, Campylobacter 
High 
No. 070414 YES  Industrial Natural Broiler carcasses E. coli High 
No. 100901 YES   Laboratory Inoculated Broiler thighs S. Typhimurium, Campylobacter, E. coli Low 
(Waldroup et al., 1992) NO Control contamination 
level too low to allow 
quantification of 
reductions 
Industrial Natural Broiler skin Listeria monocytogenes  
Waldroup et al. (1999) YES  Industrial Natural Broiler carcasses APC, Coliforms, E. coli, Campylobacter High 
(Waldroup et al., 2000a) YES  Pilot Natural Broiler carcasses APC, Coliforms, E. coli, Campylobacter High/ 
Medium 
(Waldroup et al., 2000b) NO Control contamination 
level too low to allow 
quantification of 
reductions 
     
                                                     
10  Although the application of the formulated product is intended to reduce the prevalence and/or numbers of target pathogenic microorganisms, data on the counts of non-pathogenic 
microorganisms, such as indicator microorganisms and total viable counts, should be provided and may also assist in the assessment of the overall efficacy of the proposed application. 
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3.4. Statistical significance and statistical methods used 
Statistical analysis was performed in data of all experiments except for the in-house studies Nos. 
060607 and 060613. Either analysis of variance (ANOVA) or generalised linear models (GLM) were 
used, followed by different methods for multiple comparisons (Newman-Keuls multiple range 
analysis, Duncan's multiple range test, Tukey-Kramer‟s test or means separation with least square 
means) to divide treatments into groups with significantly different means. These methods differ in 
their way to control for family-wise/experiment-wise error rates (i.e. incorrect rejection of the null 
hypothesis that all means are equal because of the inflated Type I error rate due to the multiple tests 
performed on the same set of data). Only the Tukey-Kramer's test is exact in this respect. An 
alternative choice would have been the use of Dunnett's test for pairwise comparisons with a defined 
control group (i.e. the untreated or water treated samples). Nevertheless, the log-reductions 
documented in the application are meaningful, and there is clear evidence of increasing effects with 
increasing concentrations of CPC. The BIOHAZ Panel therefore considers the documented reductions 
as biologically relevant. 
3.5. Additional information provided by the applicant in the dossier 
o The microbiological analytical methods used are variants of conventional culture methods. In 
addition a proprietary PCR method based on ribotyping (BAX, Dupont Qualicon) for Salmonella 
identification was used, which was stated as approved by AOAC. The applicant has extensively 
used Petrifilm® to enumerate coliforms and E. coli. These methods have been certified by AFNOR 
on the basis of EN ISO 16104. 
o In one peer-reviewed study (Beers et al., 2006) the authors sampled visibly contaminated carcasses, 
although these carcasses would be trimmed according to EU Reg. 853/2004, Annex III, chapter IV, 
point 10 “The carcasses must not contain visible faecal contamination. Any visible contamination 
must be removed without delay by trimming or alternative means having an equivalent effect.” 
o Although quaternary ammonium compounds (QACs) such as CPC are bactericidal, the application 
dossier does not indicate the mode or mechanism of action.  
o The Cecure® recycling system is designed to adjust automatically the concentration through the 
use of spectrophotometer. The dossier indicates that the recycled Cecure® solution has been 
demonstrated not to contain microbial contamination under the proposed conditions of use by 
referring to a study by Breen et al. (1995). Since in this report evidence is provided only for S. 
Typhimurium in pure cultures, this conclusion cannot be generalised to include other bacterial 
species or bacterial spores. 
o It is stated in the dossier that there is no decrease in efficacy when using recycled Cecure® 
solution. This conclusion, however, is based on only one experiment conducted on ten carcasses. 
Moreover the test was performed not on the recycled solution but on the diluted stock solution of 
carcass drip and compared to CPC diluted in tap water; this may not represent the real situation and 
needs confirmation.  
o Further, by analysing the results, it may be argued that the counts after treatment with Cecure® 
dissolved in carcass drip were more variable than the counts after treatment with Cecure® 
dissolved in water. Finally, the difference between the counts in the two groups was not tested for 
statistical significance. 
3.6. Evaluation of studies 
3.6.1. Peer reviewed papers 
Two laboratory studies of low strength of evidence were conducted with chicken skin (Arritt et al., 
2002; Breen et al., 1997). One involved inoculation of irradiated chicken skin with Salmonella 
Typhimurium (Breen et al., 1997) and found that 1% CPC for 1 min reduced counts by 0.6 log10 
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cfu/2.5 cm2 of skin compared to the untreated control. In the other laboratory study (Arritt et al., 2002) 
chicken skin was inoculated with Campylobacter jejuni; sprayed at 8 psi, 21°C, with 0.1 and 0.5% 
CPC (1 and 5 mg/ml) for 1, 3 or 10 min, and stored for 10 min without rinsing. When treated for 1 min 
with 0.5% CPC, counts were reduced, compared to the untreated control, by 2.9 log10 cfu/ml.  
One pilot scale study (Li et al., 1997) of medium strength of evidence evaluated, by spraying in a test 
chamber (30, 60, or 90 sec), CPC (0.1% at 22oC) on pre-chill broiler carcasses inoculated at 6 log10 
units with S. Typhimurium; the carcasses were rinsed with water after treatment. Reductions achieved 
(15 carcasses and 3 replicates), in addition to water treatment, after a 30 sec treatment at 207, 345 and 
827 kPa were 0.5, 0.5 and 0.9 log10 cfu/bird. After a 90 sec treatment, the corresponding reductions 
were 1, 1 and 1.6 log10 cfu/bird. Spraying pressure and time of exposure appeared to have no major 
influence on efficacy of CPC against Salmonella. 
One industrial scale study (Baker et al., 2010) evaluated the effect of 0.3% (3 mg/ml) Cecure® under 
industrial conditions on whole carcasses post-chill and found that initial APC were reduced by 0.5 to 
>1.0 log10 units compared to the control. The other industrial scale peer-reviewed published study 
(Beers et al., 2006) considered in the evaluation, also examined broiler carcasses with natural 
contamination. The carcasses evaluated needed re-processing and were treated by spraying in a 4-
linear foot cabinet after the last inside-outside bird washer and before the chiller with 0.5-0.7% 
Cecure® by spraying for 2-3 sec at line speeds of 11-70 birds/min in three plants. Samples were taken 
for analysis, after 45-60 sec of dripping, but prior to immersion chilling. Based on testing of 180-200 
samples per treatment over a 12-week period, initial counts of APC, E. coli, coliforms and 
Campylobacter were 3.7-4.9, 1.8-3.1, 1.3-2.9 and 1.8-3.1 log10 cfu/ml, respectively. For the 
corresponding above microbial groups, mean (standard deviations were in the range 0.3-1.3) 
reductions by Cecure® compared to untreated controls, were 2.5-3.9, 1.6-2.9, 1.2-2.7 and 0.8-2.1 log10 
units , respectively. Relative prevalence of Salmonella and Campylobacter were reduced by 50-95 and 
90-97 %, respectively.  
3.6.2. In-house studies 
3.6.2.1. High strength of evidence  
Pre-chill application. Of the four industrial scale studies with high strength of evidence conducted 
with broiler carcasses at the pre-chill level (Nos. 060302, 060401, 061010, and 070414), data of the 
pre-chill application component of study No. 060302, indicated that applying Cecure®, at 0.1 % (1 
mg/ml CPC), reduced coliforms over untreated controls by 0.5 log10 cfu/ml. When applied at 0.9 and 
3.8 litres/bird, corresponding reductions in E. coli were 0.5 and 0.7 and in APC 0.5 and 0.7 log10 
cfu/ml respectively. In the same study, the Cecure® concentration of 0.6 % achieved reductions of 2.0 
(coliforms, 0.9 litres/bird), 1.6 (coliforms, 3.8 litres/bird), 2.0 (E. coli, 0.9 litres/bird), 1.5 (E. coli, 3.8 
litres/bird), 2.6 (APC, 0.9 litres/bird), and 2.1 (APC, 3.8 litres/bird) log10 cfu/ml. Volume applied per 
bird (0.9 versus 3.8 litres/bird) had no major influence, while the concentration of 0.6 % was more 
effective than the 0.1 %. 
In study No. 060401, based on treatment with 2.2 litres/bird, reductions of APC and E. coli, at 35 
birds/min treated with 0.05% Cecure® (0.5 mg/ml CPC) were 1.7 and 1.5, and 2.2 and 0.8 log10 cfu/ml 
over controls and water treatment, respectively, while Salmonella was present in 60% and 0% of water 
and Cecure® treated samples, respectively. Corresponding reductions at 70 birds/min were 1.0 and 
0.8, and 1.5 and 0.2 log10 cfu/ml.  APC and E. coli reductions (cfu/ml) at the concentration of 0.6 % (6 
mg/ml CPC) were 3.5 and 3.3, and 2.6 and 1.3 (at 35 birds/min), 3.5 and 3.3, and 2.6 and 1.3 (for 70 
birds/min); no Salmonella were recovered. The rate of carcass processing pre-chill (35 versus 70 per 
min) had no major influence on extent of microbial reductions.  
In study No.061010, Cecure® at concentrations of 0.2 and 1.0 % (2 and 10 mg/ml CPC), applied at 
3.8 litres/bird as a 60 sec drench at a rate of 70 birds/min, on broiler carcasses pre-chill, reduced over 
water-treated controls, APC, Enterobacteriaceae, Pseudomonas, coliforms, E. coli and Campylobacter 
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by 3 and 3.4, 1.7 and 1.8, 0.8 and 1.1, 1.6 and 1.7, 1.5 and 1.6, and 0.7 and 0.7 log10 units, 
respectively. Based on these data, under the conditions evaluated, Cecure® had similar efficacy 
against most of the microbial groups examined and at both concentrations tested; it was more effective 
against APC. 
In study No. 070414 conducted at industrial level, Cecure® applied pre-chill on naturally 
contaminated broiler carcasses by drenching at 3.8 litres/bird and at a concentration of 0.6 % (6 mg/ml 
CPC) leads to a reduction of E. coli over control by 1.0 log10 cfu/ml. 
Post-chill application. Five (Nos. 060302, 060401, 060407 and 060510, and Waldroup et al., 1999) 
industrial scale studies of high strength of evidence were conducted with broiler carcasses post-chill.  
In the post-chill component of study No. 060302, Cecure® treatment applied at 0.1% (1 mg/ml CPC) 
reduced APC, coliforms and E. coli over untreated controls by 1.4 and 2.1, 0.5 and 0.9 and 0.4 and 0.8 
log10 cfu/ml when applied at 0.9 and 3.8 litres/bird, respectively. In the same study, the concentration 
of 0.6% achieved reductions of 2.1 (APC, 9 litres/bird), 2.3 (APC, 3.8 litres/bird), 1.0 (coliforms, 0.9 
litres/bird), 1.1 (coliforms, 3.8 litres/bird), 0.8 (E. coli, 0.9 litres/bird), and 0.9 log10 cfu/ml (E. coli, 3.8 
litres/bird). Thus, application volumes of 0.9 and 3.8 litres/bird had no major effect on extent of 
reductions, which were generally higher at the concentration of 0.6 % compared to 0.1 %. 
In the post-chill component of study No. 060401 reductions of APC and E. coli, on samples treated 
with 0.05 % Cecure® (0.5 mg/ml CPC) at 35 birds/min, were 3.0 and 2.4, and 1.9 and 1.5 log10 cfu/ml 
over controls and water treatment, respectively, while samples were Salmonella positives at rates of 
20% and 0% in control and Cecure® treated products, respectively; corresponding reductions at 70 
birds/min were 2.4 and 1.7, and 1.5 and 0.1 log10 cfu/ml, and treated samples were 20% Salmonella 
positive. APC and E. coli reductions at the concentration of 0.6% (6 mg/ml CPC) were 3.2 and 2.6, 
and 1.9 and 1.5 (for 35 birds/min), and 3.2 and 2.6, and 1.9 and 1.5 (for 70 birds/min) log10 units; 
Samples were positive for Salmonella at rates of 0% for control and treated products. The rate of 
carcass processing post-chill (35 versus 70 per min) had no major influence on extent of microbial 
reductions. 
Study No. 060407 involved use of 0.4% Cecure® (4 mg/ml CPC) on broiler carcasses, at 70 
birds/min. Reductions of APC, coliforms and E. coli on samples treated with 2.2, 3.0, 4.9 and 5.7 
litres/bird were 2.1, 2.4, 2.3 and 2.0, 1.3, 1.8, 2.1 and 1.0, and 1.0, 1.7, 2.0 and 0.9 log10 units, 
respectively. Thus, volumes applied in the range 2.2 to 5.7 litres/bird were similar in efficacy. 
In study No. 060510, treatments of 0.1, 0.2, 0.3, and 0.4% (1, 2, 3, 4 mg/ml CPC), applied at flow 
rates of 176-465 litres/min and treatment volumes of 0.25-0.70 litres/bird, reduced APC over untreated 
controls on post-chill treated carcasses in two replicates by 1.9-2.5 log10 units, indicating no major 
effect of concentration, flow rate and treatment volume in the ranges tested. 
Waldroup et al. (1999) evaluated the decontaminating activity of CPC and Cecure®, each in one of 
two plants. The studies evaluated post-chill naturally contaminated broiler carcasses by spraying at 40-
60 psi, 0.25-0.4 % CPC equivalent, at 0.06-0.12 litres/bird, on 70-90 birds/min for 2-3 sec exposure 
time. Samples were analysed after 3 min of dripping following treatment, without rinsing. In the study 
evaluating CPC (Plant-1), log10 reductions of APC, coliforms, E. coli and Campylobacter over 
untreated controls at concentrations of 0.25 % and 0.4 % were 0.9 and 2.0, 0.7 and 0.8, 0.7 and 0.9, 
and 0.4 and >2.0; Salmonella positive samples were too low to allow comparisons. In the study 
evaluating Cecure® (Plant-2), the treatment reduced counts of APC, coliforms, E. coli and 
Campylobacter over control samples to below the detection level of 1 cfu/ml.  
3.6.2.2. High/medium strength of evidence 
Pre-chill application. Waldroup et al. (2000a) evaluated Cecure® on naturally contaminated broiler 
carcasses pre-chill in a pilot plant. Reductions of APC, coliforms, E. coli and Campylobacter over 
water-treated controls by misting for 3 sec at concentrations of 0.2 % and 0.5 % (2 and 5 mg/ml CPC) 
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were 1.1 and 1.6, 0.7 and 0.9, 0.3 and 0.3, and 1.0 and 1.5 log10 cfu/ml, respectively. Corresponding 
reductions achieved when 0.2 and 0.5 % was applied by dipping for 10 sec were 1.3 and 2.6, 0.8 and 
1.3, 0.2 and 0.6, , 1.5 and 1.6 log10 cfu/ml. Dipping may have achieved somewhat higher reductions 
compared to misting. 
3.6.2.3. Medium strength of evidence 
Post-chill application. Pilot scale study No. 060607 involved 0.2, 0.4, 0.6, 0.8 and 1.0% Cecure® (2, 
4, 6, 8 mg/ml CPC) applied post-chill on carcasses inoculated with E. coli isolated from a carcass 
rinsate under laboratory conditions. Treatments applied at 0.2 and 0.4 % (0.95 litres/bird and at 151 
litres/min), achieved reductions of APC, coliforms and E. coli over control samples of 1.4 and 2.2, 1.7 
and 2.7, and 1.6 and 2.7, log10 cfu/ml, respectively.  Corresponding reductions on water treated 
samples were 0.7 and 1.6, 0.8 and 1.9, and 0.5 and 1.8 log10 cfu/ml. Reductions of APC, coliforms and 
E. coli over untreated control samples at 0.6 % concentration applied at 0.95 litres/bird were 4.3, 4.0 
and 4.0 log10 units. Corresponding reductions at 0.8% (0.95 litres/bird) were 4.9, 4.5 and 4.5 log10 
units. Reductions at 0.6 % concentration applied at 1.9 litres/bird were 4.4 and 3.5, and 4.4 and 3.7 
log10 units. At 0.95 litres/bird and 0.8 %, reductions were 4.5, 4.4 and 4.4 log10 units.  Reductions at 
1.0 concentration were similar to those at 0.6-0.8%. It appears that reductions increased with Cecure® 
concentrations up to 0.6 %, while volume applied per bird (0.95 and 1.9 litres/bird) and flow rate (151 
and 303 litres/min) had no major influence in the ranges tested. 
Study No. 060613 was conducted on E. coli and Salmonella inoculated (6 log10 units) broiler carcasses 
treated with Cecure® in a laboratory. At 0.95 litres/bird, concentrations of 0.2, 0.4, 0.6, 0.8, and 1.0 % 
CPC (2, 4, 6, 8 and 10 mg/ml CPC) caused reductions, over water-treated samples, of 2.2 and 2.8, 4.6 
and 3.8, 4.8 and 5.0, 4.8 and 5.0, and 4.8 and 5.0 log10 cfu/ml, respectively. Reductions at 1.9 
litres/bird at concentrations of 0.6, 0.8 and 1.0 % CPC over water-treated controls were 4.8 and 5.0, 
4.8 and 5.0, and 4.8 and 5.0 log10 cfu/ml. These data also indicate that concentrations of CPC above 
0.6% do not increase reductions, which are not affected by volume applied per bird in the range 
examined. 
3.6.2.4. Other studies 
Study No. 10090111 evaluated effects of 0.5 and 1.0% Cecure® (5 and 10 mg/ml CPC) on the counts 
of S. Typhimurium, Campylobacter and E. coli inoculated on skin-on broiler thighs at 0 time after 
treatment and after 7 days of refrigerated storage. The inoculated thighs were treated by misting or 
drenching. On day 7, APC of control samples reached 8.7 log10 cfu/ml, while APC of samples treated 
with 0.5% and 1.0% Cecure® reached 7.0-7.7 log10 cfu/ml. As expected, counts of E. coli, coliforms, 
and Campylobacter, regardless of inoculation level (low or high) or percent Cecure® (0.5% or 1.0%), 
did not increase during refrigerated storage. It was concluded that there is no sublethal recovery of 
potential human pathogens during refrigerated shelf life of raw poultry products that have been treated 
with Cecure® under the proposed conditions of use. 
3.6.3. Efficacy of decontamination of different CPC concentrations: comparison of in-house 
studies 
In order to compare the results regarding the efficacy of decontamination obtained in different in-
house studies, as an example in Figure 1, the relative log10 reduction of E. coli contamination in pre- 
and post-chill carcasses (treated vs water rinsed samples) at different Cecure® concentration is 
presented. 
The graph shown in Figure 1 may suggest that for studies Nos. 060613, 060401 and 60607, and 
Waldroup (2000a) there is an increasing decontamination effect with increasing concentrations of 
CPC, especially between 0.2% and 0.6%. In study No. 060613, where five different concentration 
levels were tested (ranging from 0.2% to 1%), beyond 0.6% concentration no more increase on the E. 
coli reduction was detected. Nevertheless, this finding should be confirmed by comparing data from 
                                                     
11  Low strength of evidence, not included in the table A in Appendix 
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more studies conducted under similar conditions. In fact it can be observed that, at 0.6% CPC 
concentration, there was high variability in reduction levels among the studies of which the results are 
shown in Figure 1. This can be due to the variable experimental conditions in the different trials such 
as the initial level of contamination that may influence considerably the reduction efficacy. 
 
Figure 1:  Reduction of E. coli contamination in pre- and post-chill carcasses (treated versus water 
rinsed samples) at different Cecure® concentrations in different in-house studies. 
3.4. Conclusions 
 Studies, considered in evaluating efficacy, included peer-reviewed published papers and in-
house conducted studies. The studies considered were mostly of industrial scale with some of 
pilot and laboratory scale, and most evaluated naturally contaminated samples. Studies 
considered were classified as of high, high/medium, medium, and low strength of evidence. 
 Both Cecure® and its active ingredient CPC were found efficacious in reducing pathogenic 
contamination on fresh broiler carcasses or chicken skin, when applied pre- and post-carcass 
chilling. 
 Overall reductions of various pathogenic microorganisms on fresh broiler carcasses were in 
the range of <1.0 to 5.0 log10 units over untreated and water-treated controls. The lower 
reductions are generally associated with lower concentrations of CPC (e.g., 0.1% or 1 mg/ml 
CPC) applied to samples of low initial contamination, while the higher reductions were 
achieved with inoculated samples. 
 Based on the results of a peer reviewed published paper: 
o Cecure®, applied as proposed in the application, reduced coliforms, E. coli and 
Campylobacter counts by 0.6-2.7 log10 units more than water treatment; Salmonella 
and Campylobacter relative prevalence was reduced by 50-95% and 90-97%, 
respectively. 
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 Based on data from in-house studies: 
o Most studies found Cecure® effective against APC, coliforms and E. coli, certain 
studies demonstrated activity against Salmonella and Campylobacter, while one study 
found it also effective against Enterobacteriaceae and Pseudomonas. 
o Evidence provided to support that the recycled Cecure® solution is as efficacious as 
the fresh solution was not adequate.  
 Other conclusions 
o Considering the reduction of E. coli contamination in pre- and post-chill carcasses the 
results from four in-house studies may suggest that the concentration of 0.6% CPC 
was more effective than 0.1% CPC, while concentrations above 0.6 % CPC did not 
further increase microbial reductions. This should be confirmed by further 
experimental evidence. 
o Spraying pressure and time of exposure did not appear to have a major influence on 
efficacy of CPC against Salmonella. 
o Volume of solution applied (0.9-5.7 litres/bird) had no major influence on efficacy 
against coliforms and E. coli. 
o In the range tested (151 and 303 litres/min), flow rate had no major influence on 
efficacy. 
o The rate of carcass processing (35 versus 70 birds per min) had no major influence on 
extent of microbial reductions, both in pre- and post-chill Cecure® applications.  
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4. The potential emergence of reduced susceptibility to biocides and/or resistance to 
therapeutic antimicrobials linked to the use of the formulated product  
4.1. Introduction 
In relation to the potential emergence of reduced susceptibility to biocides and / or resistance to 
therapeutic antimicrobials linked to the use of the formulated product, the applicant has provided the 
following argumentations:  
i. The potential human pathogenic organisms of concern on raw poultry would not be 
exposed to low levels of CPC in the production because:  
a. CPC is not utilized as a disinfectant or sanitizer in the production of live poultry;  
b. CPC binds so tightly to poultry offal that it is not bio-available to function as an 
antimicrobial, and, moreover, at EU level live poultry are not fed poultry meat and 
bone meal (as happens in the USA); and 
c. The concentrations to which potential pathogens will be exposed in the processing 
facility, for the purpose of microbial reduction, are very high. The applicant 
provides studies and trials showing that CPC residues in poultry by-product meat 
and bone meal is irreversibly tightly bound to these products in a biologically 
inactive form, which negates the concern for microbial resistance via this route 
(Table 25 and 26, page 154 of the dossier). Moreover, the applicant concluded 
from this observation that CPC bound to offal material has no antimicrobial 
activity (pg. 189). 
ii. According to the EFSA guidance (EFSA, 2010), tests about development and 
dissemination of acquired reduced susceptibility to biocides and/or resistance to 
therapeutic antimicrobials in environmental microorganisms and a post-market evaluation 
are not required for Cecure®. This is because it is stated that the antimicrobial solution is 
neutralized prior to discharge of wastewater (as described in Section 7.1.3. and in the 
study entitled “Neutralization of Cetylpyridinium Chloride (CPC) with Activated Carbon” 
Section 2.5.2.7. of the dossier). 
4.2. Comments on information provided 
The active constituent of the formulated product is CPC. This substance is a cationic Quaternary 
Ammonium Compound (QAC), which is classified as an antiseptic agent, and has been used alone or 
in combination with other drugs for oral and health care. It is used also as a preservative in 
pharmaceutics and in cosmetics.  
The following aspects of its proposed use as a decontamination agent in poultry in respect of the 
development of reduced susceptibility to biocides and / or resistance to therapeutic antimicrobials have 
not been taken into consideration by the applicants: 
4.2.1. Development of resistance to biocides and therapeutic antimicrobials. 
In a study of changes in antimicrobial susceptibility in Pseudomonas stutzeri following exposure to 
gradually increasing concentrations of chlorhexidine diacetate or CPC, strains were shown to develop 
stable resistance to these compounds and also reduced sensitivity to biocides such as triclosan and 
therapeutic antibiotics such as nalidixic acid, erythromycin and ampicillin (Tattawasart et al., 1999). A 
more recent study has demonstrated that exposure of a wild-type strain of Serratia marcesens to CPC 
resulted in the formation of a QAC-resistant mutant exhibiting 2- to 16- fold more resistance to 
biocides and antibiotics, including CPC, benzalkonium chloride, chlorhexidine gluconate, 
fluoroquinolones, tetracyclines and chloramphenicol than did wild-type strains (Maseda et al., 2009). 
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The mechanism of resistance involved mutational up-regulation of a multidrug efflux pump in the 
mutant strain.  
As the primary mechanism of resistance development in relation to the use of CPC involves changes 
in efflux, it is unlikely that the use of this compound will result in the appearance and / or selection of 
microbes (both pathogens and non-pathogens) with new enzymatic-based resistance to therapeutic 
antibiotics. Nevertheless the possibility of mutational changes in global regulatory genes as a 
consequence of exposure to such compounds either at high concentrations or for long periods resulting 
in „low level‟ resistance has not been fully considered. Horizontal transfer of such resistances from 
non-pathogens to pathogens is unlikely to occur by conjugation, which is for the most part confined to 
plasmids, transposons and integrons, but is theoretically possible, albeit at very low level, by natural 
genetic transformation of the mutated global regulatory genes (Courvalin, 2008; EFSA, 2010). Such 
considerations (i.e., changes in global regulatory genes) may also apply to the development of reduced 
susceptibility to biocides (Karatzas et al., 2008). 
4.2.2. Selection for resistance to biocides and therapeutic antimicrobials. 
An area of special concern is the potential for selection of bacteria carrying QAC determinants linked 
to therapeutic resistance determinants in mobile genetic elements. 
QAC determinants are often associated with mobile genetic elements in different bacterial species, 
either in plasmids or class 1 integrons (Bjorland et al., 2003; Heir et al., 1998; Kazama et al., 1998; 
Machado et al., 2008; Paulsen et al., 1996; Poole, 2002). Class 1 integrons have been associated with 
antimicrobial resistance (AMR) in many Gram-negative organisms and are characterized by the 
presence of a 5′ conserved segment (5′-CS) containing an integrase gene (intI1), a 3′ conserved 
segment (3′-CS) containing qacEΔ1 and sul1 genes, and a central attI recombination site which may 
contain a gene cassette(s) (Hall and Collis, 1998). For example, together with the qacEΔ1 gene, the 
ampicillin, chloramphenicol/florfenicol, streptomycin, sulphonamides and tetracycline resistance 
genes in the well-characterised strain of S. Typhimurium definitive phage type (DT) 104 (=DT104) 
(Threlfall, 2000), reside within the 43-kb chromosomally-encoded Salmonella Genomic Island 1 (SGI-
1). SGI-1 is transferable by mobilisation and transduction has become widely disseminated, both by 
the worldwide spread of DT104 and also by horizontal transfer, to at least 15 other serovars of 
Salmonella and also to Proteus spp. (Mulvey et al., 2006). Additionally, there are a number of 
examples of co-resistance to QAC and other antimicrobial agents by linkage on the same genetic unit 
such as plasmids, transposons or integrons, or on a combination of these (Antunes et al., 2007; 
Hegstad et al., 2010; Naas et al., 2001; Norman et al., 2008). 
4.2.3. Target organisms 
In the application it is stated that Cecure® will be used as a food processing aid to control the 
following organisms on raw poultry carcasses and skin-on poultry parts: Salmonella, Campylobacter, 
Listeria, Staphylococcus aureus, Escherichia coli (including O157:H7), Pseudomonas, total coliforms, 
viruses, and other naturally occurring microorganisms on raw poultry carcasses (page 12 of the 
dossier). Elsewhere in the document the applicant has stated that „the potential human pathogenic 
organisms of concern on raw poultry, primarily Salmonella and Campylobacter, would not be exposed 
to low levels of CPC in the production‟ (section 6.2).  
As far as can be observed from the dossier, there have been no tests undertaken to monitor the 
development of resistance to therapeutic antimicrobials and to biocides in the above organisms, either 
under the conditions of use or in wastewater. 
4.2.4. Antimicrobial activity of CPC in organic material 
The applicant concluded that CPC residues in poultry offal do not have antimicrobial activity; this 
negates the concern for the development of microbial resistance via these routes (Table 25 and 26 of 
the dossier). This opinion is supported in data from trials showing that when offal containing a certain 
concentration of CPC was added to a culture of one bacterial strain, the level of bacterial growth was 
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not different from that observed for the offal alone. The description of the experimental design is very 
concise and no specification on the CPC concentration tested is provided. Lack of details on the 
analytical method and strain source were also apparent. Samples with different amounts of CPC and 
several species with different MICs should have also been tested. In view of these shortcomings the 
results are not considered useful for supporting the absence of antimicrobial activity of CPC in offal 
material.  
4.3. Conclusions  
 Data to address the issue of the potential emergence of reduced susceptibility to biocides 
and/or resistance to therapeutic antimicrobials linked to the use of CPC have not been 
provided; 
 Data to address the issue of the potential selection of isolates with reduced susceptibility to 
biocides and/or resistance to therapeutic antimicrobials linked to the use of CPC have not been 
provided; 
 There are reports of the development/selection of resistance to biocides and therapeutic 
antibiotics in some organisms following exposure to CPC; the principal mechanism of 
resistance involves up-regulation of a multidrug efflux pump; 
 In some pathogenic bacteria the dissemination of antibiotic resistance genes may be facilitated 
by the linkage between such genes and qac genes; 
 The development of enzymatic resistance to biocides and/ therapeutic antimicrobials as a 
result of exposure to CPC is highly unlikely; 
 As far as can be observed from the dossier, there have been no tests undertaken to monitor the 
development of resistance of the target organisms to biocides and/or therapeutic 
antimicrobials either under the conditions of use, or in wastewater; 
 Evidence is not provided about testing potential contamination of Cecure® solution in the 
recycling process for all bacterial species;  
 Data provided were not considered useful to support the absence of antimicrobial activity of 
CPC in organic material such as poultry offal. 
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5. The risk related to the release of the slaughterhouse and/or processing plant effluents, 
linked to the use of the formulated product, into the environment.  
Basic data necessary for an assessment of the effect of Cecure® on the environmental compartments 
surface water, sediment and soil as well as for evaluation of the function of sewage treatment plants 
were either not provided by the applicant or could not be validated by the CEF Panel. The CEF Panel 
is aware that additional data relevant for the environmental risk assessment of Cecure® have been 
generated within the context of data requirements for biocides. However these data were not available 
to EFSA. 
All the relevant data provided by the applicant were critically evaluated. When considered invalid or 
when data were lacking, additional information from the open literature was used to perform a 
preliminary environmental risk assessment for CPC from the use of Cecure®. The methodology of this 
assessment was based on the EU Technical Guidance Documents (TGD) for the  risk assessment of 
biocides and industrial chemicals. The software system EUSES 2.1.1, developed for quantitative 
assessment of the risks of these chemicals to man and the environment, has been used to estimate the 
distribution of CPC in the environment and to calculate the predicted environmental concentrations 
(PECs). This is described in section 5.1. In section 5.2 the predicted no effect concentrations (PNECs) 
are presented, which in section 5.3 are compared with the PECs to characterise the risk for the 
different environmental compartments. The overall conclusions are presented in section 5.4.  
5.1 Exposure assessment 
5.1.1. Environmental releases 
Cecure® can either be applied on pre-chilled raw poultry carcasses prior to immersion in a chiller or 
on post-chilled carcasses. In the pre-chilled application, after the carcasses exit the treatment cabinet, a 
drip tray running below the process line will collect liquid dripping from the carcasses and recycle it. 
CPC that drips from the carcasses for the remainder transit time to the chiller will not be captured and 
recycled. During immersion chilling, residues of CPC will be released into the rinse solution. The 
combination of CPC in the drip collected plus the mass of CPC found in the rinse water represents the 
mass of CPC that is not recycled. 
In the post-chilled application after the carcasses exit the treatment cabinet, a drip tray running below 
the process line will collect liquid dripping from the carcasses and recycle it. The carcasses will then 
enter a potable water rinse cabinet, followed by an additional drip time before further processing or 
packaging. The combination of CPC in the rinse water plus CPC in the post-rinse drip represents the 
mass of CPC that is not recycled. 
The applicant provided a study in which the mass of non-recycled material per carcass in both pre-
chilled and post-chilled application at the concentration proposed in the dossier was determined. This 
total mass of CPC found in the drip and rinse solutions can be used to determine the environmental 
exposure of CPC from the application process. For the diluted Cecure® solution the total non-recycled 
mass was 7.8 and 8.9 mg per carcass for the pre-chilled and post-chilled, respectively. 
To determine the total release from slaughterhouses, the same scenario is taken as in the Scientific 
Committee on Health and Environmental Risks (SCHER) opinion12 by assuming that 50 tons of 
poultry meat is processed per day. This value is the threshold designated by the Integrated Pollution 
Prevention and Control (IPPC) Directive13. The European Pollutant Emission Register (EPER) 
database indicates that just a few slaughterhouses in the EU are above this limit. The very large 
                                                     
12  Scientific Committee on Health and Environmental Risks (SCHER) and of Scientific Committee on Emerging and Newly 
Identified Health Risks (SCENIHR). Environmental impact and effect on antimicrobial resistance of four substances used 
for the removal of microbial surface contamination of poultry carcasses. The SCHER adopted this opinion at its 22nd 
plenary on 12 March 2008; The SCENIHR adopted this opinion at its 23rd plenary on 02 April 2008. 
13  Best Available Techniques in the Slaughterhouses and Animal By-products Industries, European IPPC Bureau, 2005 
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facilities, exceeding this production level, have specific environmental controls through the IPPC 
Directive. However, since the large majority of slaughterhouses in the EU are below this limit, the 50 
tons meat per day limit is considered appropriate for a generic assessment.  
Based on an average slaughter weight of a broiler of 1.2 kg, the number of carcasses processed per day 
is around 42000 carcasses per slaughterhouse. This would mean that around per day 0.33 and 0.37 kg 
CPC will not be recycled in pre-chilled and post-chilled application, respectively, and be disposed 
with the wastewater of the slaughterhouse.  
Slaughterhouses in the European Union are divided between those that treat their waste water on-site 
and discharge directly to the local water course and those that discharge their waste water to the local 
municipal sewage treatment plants (STP) with the permission of their local sewerage company. The 
latter category carry out some pretreatment of the waste water on-site, usually to at least screen solid 
materials, although they may also undertake other treatments, like Dissolved Air Floatation (DAF).  
The applicant did not provide data on the removal efficacy of the pre-treatment systems in the EU. In 
the FDA environmental risk assessment report (as provided by the applicant, publicly not available) it 
was assumed in all slaughterhouse waste water was treated in DAF generator with a removal 
efficiency of 99%. DAF uses very fine air bubbles to remove suspended solids. The suspended solids 
float to the top of the liquid and form foam, which is then skimmed off.  
Based on the information given in the Refinery Best Available Technique Reference Document (IPPC, 
2005) many large slaughterhouses in the EU use a DAF treatment plant to further treat their waste 
water prior to discharge to surface water. Alternatively, some large slaughterhouses have installed 
biological treatment plants which convert soluble and colloidal materials into biosolids. These are 
usually activated sludge plants which, depending on their capacity, may be preceded by sedimentation 
or DAF. At present insufficient information is available to validate the removal efficacy of an on-site 
DAF treatment plant or an alternative biological treatment plant. For this reason only the 
environmental risk related to discharge of waste water to the local municipal sewage treatment plants 
will be assessed.  
5.1.2. Environmental fate and distribution 
5.1.2.1. Degradation and transformation in the environment 
No information on the degradability of CPC has been provided by the applicant.  In a GDCh-Advisory 
Committee on Existing Chemicals report (BUA, 2003) it is mentioned that CPC is not readily 
biodegradable: in a closed bottle test (OECD 301D) 25 % was eliminated, based on the theoretical 
oxygen demand, in 28 days. Based on the chemical structure CPC is not expected to hydrolyse. In this 
preliminary risk assessment it is assumed that CPC is not readily biodegradable.  
5.1.2.2. Adsorption 
The applicant submitted an FDA assessment report (FAP 2A4736, environmental assessment) 
including data on the adsorption of CPC to DAF, sludge and soil, showing that the substance is very 
adsorptive. However, the description of the experimental setup is very limited and no specification on 
the DAF, sludge or soil type is given. Also the number of samples is very small. No details on the 
analytical method are given. Overall, it does not seem that any standard protocol is followed. As only 
one type of each matrix is examined the representativeness of the data is rather questionable. 
Furthermore, the results do not allow determination of a partitioning coefficient of CPC for any of the 
matrices. In view of these shortcomings the results are not considered useful for the environmental risk 
assessment.  
Based on information found in the scientific literature, it appears that quaternary ammonium 
compounds (QACs) have a high affinity to adsorb on biosolids. Cumming et al (2011) investigated the 
sorption of QACs to humic acid and derived an adsorption coefficient (Kd) value of 52000 L/Kg for 
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CPC. According to the researchers the concentrations of the humic acid employed were comparable to 
suspended solids levels in the influent of STPs. The available information was however insufficient to 
validate the Kd value proposed by the applicant nor could the assumption be verified.  
Based on an adsorption study with different sludge types with four QACs belonging to either 
monoalkonium or benzalkonium Ismail et al. (2010) concluded that the affinity depends mainly on the 
QAC structure rather than the sludge type and composition. QACs with a longer alkyl chain adsorb 
more than QACs with a shorter alkyl chain. The benzyl group further enhances the adsorption of 
QACs, but this effect diminishes as the alkyl chain length increases. The mechanism of QAC sorption 
on biosolids is complex and both hydrophobic and ionic interactions are probably in effect. For the 
most related compound to CPC, i.e. hexadecyl benzyl dimethyl ammonium chloride (C16BDMA), an 
absorption capacity factor Kf of 20730 and 19000 L/kg determined in primary sludge and waste 
activated sludge, respectively (Ismail et al, 2010). These values are close to the Kd value of CPC 
determined with humic acid.  
In the absence of better data, the Kf values found for C16BDMA in primary and activated sludge can 
be used as first estimate of the solids-water partitioning coefficient in raw and activated sewage sludge 
of CPC to assess the fate in an STP. In order to predict the dissolved concentration in receiving waters, 
the solids-water partitioning coefficient for suspended matter is estimated to be 7000, based on the 
difference in organic carbon content between raw sludge and suspended matter.  
5.1.2.3. Elimination in Municipal Sewage Treatment Plants 
Based on the assumption that CPC is not volatile, not readily biodegradable and has a Kf value of 
20730 and 19000 L/kg for primary sludge and waste activated sludge, respectively, the removal in a 
STP is determined by using the SimpleTreat module integrated in the EUSES model which is also 
used to determine the PECs in the environment (see section 5.1.3). The standard setting of the 
SimpleTreat module represents an STP with a primary settler (producing primary sludge), an aeration 
tank (containing activated sludge) and a solids liquid separator (recycling waste sludge back to 
aeration tank). The output indicates that the overall removal of CPC in a STP is approximately 81.5 % 
via adsorption to sludge. Approximately 18.5 % is expected to be released via the effluent to the water 
recipient 
5.1.2.4. Bioaccumulation 
No information has been provided on the bioaccumulation potential of CPC. Tolls et al. (1997) have 
published a critical review on the bioaccumulative properties of surfactants. It appears that the 
bioconcentration of cation surfactants is influenced by the headgroup structure. Possibly CPC is highly 
stabilised in the lipid bilayer of the membrane which slows down and limits the uptake rate in aquatic 
species. It is therefore concluded that CPC has a low potential to bioaccumulate and no assessment of 
secondary poisoning is deemed necessary. Knezovich et al. (1989) studied the bioaccumulation and 
tissue distrubution of hexadecylpyridinium bromide in the tadpole Rana catesbeiana, the fish 
Pimephales promelas and the clam Corbicula fluminea. Whole-body bioconcentrations factors (BCFs) 
were 13 ± 4, 22 ± 8, and 21 ± 7 (mean ± SD) for tadpoles, fish, and clams, respectively. Based on the 
findings, it can be concluded that the uptake of CPC in fish is limited. It is therefore concluded that 
CPC has a low potential to bioaccumulate and no assessment of secondary poisoning is deemed 
necessary. The low BCF values also indicate that CPC does not meet the B criterium of the PBT 
(Persistent, Bioaccumulative and Toxic) or vPvB (very persistent and very bioaccumulative) 
classification (Annex XIII of the REACH Regulation).  
In view of the low vapour pressure, low bioaccumulation potential and the high adsorptive properties 
of CPC, indirect exposure of man via groundwater (as a source for drinking water), air and fish is 
expected to be negligible. Other exposure routes via uptake in plants, and transfer to milk and meat are 
difficult to assess as the current models used for quantitative estimation of these routes are driven by 
the octanol-water partition coefficient (Kow), but this parameter cannot be regarded as characterizing 
the partitioning of ionic surfactants. It is however expected that also here a slow passage through the 
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membranes will strongly limit exposure of man via these routes (i.e. low absorption of CPC from soil 
pore water by plants and also low systemic absorption of CPC from the GI-tract in food production 
animals as well as in humans). 
5.1.3. Predicted environmental concentration  
The concentrations in the environment are calculated for pre-chilled or post-chilled application in a 
slaughterhouse without an on-site treatment, in which waste water is discharged to a municipal STP. 
The fate and distribution of CPC in  the municipal STP is modelled using the SimpleTreat model 
described in the European Union System for the Evaluation of Substances (EUSES, http://ecb.jrc.it/), 
which is also used for the exposure assessments of industrial chemicals, biocides and human drugs in 
the EU. The considered default STP has a size of 10000 inhabitants. Such a STP treats 2000m3of 
waste water (house hold plus domestic waste water). In this scenario it is anticipated that the STP 
treats waste water from the slaughterhouse that already is included in the total treatment of 2000 m3. 
The other EUSES modules are used to determine the fate and distribution of CPC in the environment 
and to calculate the predicted environmental concentrations (PECs) in surface water and sediment, 
resulting from discharge of effluent (considering dilution and adsorption to suspended sediment), and 
in soil resulting from application of sludge to arable – and grassland. The PECs in effluent, surface 
water, sediment and soil resulting from the pre-chilled and post-chilled application are presented in 
Table 4. The effluent of the municipal STP will be discharged to a standard river with a flow rate of 
18000 m3/day, resulting in a dilution factor of 10. 
 
Table 4:  Calculation of PECeffluent, PECwater, PECsediment and PECsoil resulting from a pre-chilled and 
post-chilled application of CPC 
Application STP PEC effluent 
(µg/L) 
PEC surface water 
(µg/L) 
PEC sediment 
(mg/kgdw) 
PEC soil 
(mg/kgdw) 
Pre-chilled Municipal 30.5 2.76 19.3 5.66 
Post-chilled Municipal 34.2 3.09 21.7 46.4 
5.2 Effect assessment  
The aim of the effect assessment is to derive a predicted no effect concentration (PNEC) based on the 
available data. The fundamentals for derivation of PNEC are described in EU Technical Guidance 
Documents (TGD, 2003) as well as in REACH (REACH, 2008) and EFSA guidance (EFSA, 2010). 
For the aquatic compartment the minimal data requirements to characterise environmental hazard are 
acute toxicity tests performed with fish, daphnia and algae. The lowest concentration which causes 
mortality of 50% of the test organisms (LC50 value) or causes a measurable adverse effect in 50% of 
the test organisms (EC50 value) is divided by an assessment factor of 1000 in order to meet the 
uncertainties of extrapolation from mono-species laboratory tests to the aim to protect structure and 
function of the ecosystem. In principle, if the minimum data-set is not available, a PNEC cannot be 
calculated and the risk characterization cannot be performed. 
5.2.1 Sewage treatment plant (STP) 
5.2.1.1 Toxicity to microorganisms 
According to TGD (2003) in assessing toxicity of the test substance to microorganisms, the aim is to 
ensure the function of the Sewage Treatment Plant and not the protection of individual bacterial 
strains.  
Therefore tests with activated sludge are more relevant than those with single bacterial strains. The 
BUA report (BUA, 2003) states that at a concentration of 20 mg/L CPC the respiration rate was 50 % of 
Safety and efficacy of Cecure® decontamination of raw poultry products 
 
EFSA Journal 2012;10(3):2162 43 
that shown by the control (IC50) measured according to OECD 209. The non-biocidal concentration was 
1.0 mg/L. This value is used for derivation of a PNECstp. 
In addition a bacterial nitrification test showed that 15.2 mg/L of 1% Cecure® solution did not affect 
the nitrification. The test was performed in one sample tank only, and information on the density and 
the history of the inoculum is not given.The Panel therefore considered this information could not be 
used in the risk assessment   
5.2.1.2 PNEC for microorganisms in STP  
In principle a PNEC for micro-organisms in an STP cannot be derived as no reliable data have been 
provided by the applicant. Applying the non-biocidal concentration of 1.0 mg/L given in the report 
(BUA, 2003) and an assessment factor of 10 from TGD (2003), the following PNECstp is derived: 
PNECstp = NOEC / 10 = 1.0 mg/L / 10 = 0.1 mg CPC / L. 
5.2.2 Aquatic compartment 
5.2.2.1 Toxicity to algae  
No data has been provided by the applicant on the toxicity of CPC to algae.  
In the BUA report (BUA, 2003) on CPC an effect concentration (no further information) of 0.05 mg/L 
is presented, which may be used as an indication that algae are less sensitive than fish. 
5.2.2.2 Toxicity to aquatic invertebrates 
The applicant provided a table listing LC50 values for several shrimps and prawns (Macrobrachium 
rosenbergii, Metapenaeus ensis, Panaeus japonicus, P. monodom, P. penicillatus, P. semisulcatus), 
and one snail species (Biomphalaria), The LC50 values, varying from 130 to 3100 µg/L, were all 
determined after short-term exposure duration (24-48 h). Furthermore, the raw data and 
methodological details were not provided. These data are also reported in the BUA report (BUA; 
2003) as taken from a Japanese paper (written in Japanese with English summary). Therefore, the 
reliability cannot be assessed. The data therefore can be used only as a first indication that 
invertebrates may be less sensitive compared to vertebrates. 
The table also contain LOEC values for C12-pyridinium for a clam (Mercenaria mercenaria) and an 
oyster (Crassostrea virginica) after an exposure period of 14 days, effects in the range of 10 – 50 
µg/L. As the study report was not provided, the reliability of these data cannot be assessed. 
Furthermore, no argumentation is given how these data should be read across to CPC.  
5.2.2.3 Toxicity to fish 
No data has been provided by the applicant on the toxicity of CPC for fish. In the BUA report (BUA, 
2003) a 96h LC50 value for carp of 10 µg/L is reported. In the same report a 96h LC30 value of 10 
µg/L was described for the species Catostomus sp. and LC0 values were given for goldfish, catfish 
bluegill sunfish as well as rainbow trout. 
5.2.2.4 Toxicity to sediment organisms 
No data has been provided by the applicant on the toxicity of CPC for sediment organisms. 
5.2.2.5 PNEC for the aquatic compartment 
In principle a PNEC for the aquatic compartment cannot derived as no reliable data has been provided 
by the applicant. Even with complementation by data found in the open literature, and assuming these 
data are reliable, the minimum data set is not complete. To make an estimation of the potential risk, a 
tentative PNEC of 10 ng/L is calculated based on the lowest LC50 value of 10 µg/L for carp applying 
an assessment factor of 1000. 
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5.2.2.6 PNEC for sediment-dwelling organisms 
In the absence of data a tentative PNEC of 70 µg/kg dw is calculated using the Equilibrium 
Partitioning Method (EPM). In this screening procedure, described in TGD (2003) and in REACH 
guidance (2008) the concentration of CPC in pore-water (calculated from adsorption coefficients or 
log Kow) is compared with the aquatic toxicity. In this approach it is assumed that only the substance 
dissolved in pore-water is bioavailable. As other routes of exposure (eg. ingestion of sediment) are 
neglected, in case of high adsorption to sediment (log Kow>5) an additional assessment factor of 10 is 
added to the PEC/PNEC ratio. This is the case with CPC. 
5.2.3 Terrestrial compartment 
5.2.3.1 Predicted no effect concentration (PNEC) for soil-dwelling organism 
No data on the toxicity of CPC to soil-dwelling organisms has been provided by the applicant, 
therefore a reliable PNEC cannot be derived. A 5d IC20 of 50 mg CPC/L has been described in the 
BUA report (BUA, 2003) for terrestrial nematodes. No standard tests are available. Therefore no valid 
PNEC can be derived. (Chronic) tests with soil organisms (preferably plants and soil microorganisms) 
should be performed. 
Using the equilibrium partitioning approach described above for sediment-dwelling organisms, a 
tentative PNEC of 14 µg/kg dry weight (dw) is calculated. 
5.3 Risk Characterisation  
The PNECs for STP, surface water, sediment and soil are compared with the appropriate Predicted 
Environmental Concentrations (PEC), given in Table 4. If the PEC/PNEC ratio is > 1, a risk for the 
environment is apparent. If this is the case long-term tests should be performed, and on the basis of 
lower assessment factors (one chronic test: 100, two chronic tests: 50 and three chronic tests: 10) 
applied on the lowest NOEC from the long-term test the PNEC will be revised.  
As the PNEC for sediment and soil is determined by the Equilibrium Partitioning approach, according 
to the REACH guidance for highly adsorbing / binding substances (log Koc > 5) the PEC/PNEC ratios 
should be increased by a factor of 10 in order to take uptake via ingestion of sediment or soil into 
account. It should be borne in mind that this approach is considered only as a screen for assessing the 
level of risk to sediment/soil dwelling organisms. If with this method a PEC/PNEC ratio > 1 is 
derived, then (long-term) tests with sediment or soil organisms have to be conducted to support a 
refined risk assessment. In Table 5 the ratios between the PECs and PNECs in the different 
compartments are given.  
Table 5:  PEC/PNEC ratios for STP, surface water, sediment and soil, resulting from a pre-chilled 
and post-chilled application of CPC.  
Application Elimination STP  Surface water Sediment Soil 
Pre-chilled Municipal 0.3 276 2760 4040 
Post-chilled Municipal 0.3 309 3090 4530 
 
The results indicate that CPC poses no risk for municipal STP. However, for the environmental 
compartments surface water, sediment and soil, the PEC/PNEC ratios are ≥ 1. Therefore, based on the 
available data, the use of CPC in poultry slaughterhouses will pose a risk for the environment under 
the described processing conditions.  
Due to the lack of data this risk assessment can only be seen as preliminary. It could be refined by 
revising the exposure data and / or by presenting valid effect tests for the compartments surface water, 
sediment and soil. 
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5.4 Conclusions of the environmental risk assessment 
The data presented by the applicant are insufficient for a valid environmental risk assessment (ERA) 
to be carried out. Basic data necessary for an assessment of the environmental compartments surface 
water, sediment and soil as well as for evaluation of the function of sewage treatment plants were not 
provided or could not be validated.  
Using data found in the open literature predicted no-effect concentrations (PNEC) for protection of the 
function of sewage treatment plants (STP), for surface water, as well as for sediment and soil, could be 
derived based on the risk assessment methodology applied to biocides and industrial chemicals 
(REACH / TGD).  
A comparison of the predicted environmental concentrations (PEC) with the PNECs suggests that the 
use of CPC in poultry slaughterhouses does not pose a risk for the function of STP.  
As there are no indications of a high bioaccumulation potential, no risk for birds and mammals in the 
environment via indirect exposure through the food-chain (secondary poisoning) has to be expected. In 
view of the low vapour pressure, low bioaccumulation potential and the high adsorptive properties of 
CPC, indirect exposure of man via groundwater (as a source for drinking water), air and fish is 
expected to be negligible.  
Despite the fact that it is assumed that a large proportion of the active ingredient is recycled and that 
the product is assumed to be used in a specific application system claimed by the applicant, the risks 
for the environmental compartments surface water, sediment and soil are apparent. 
More specific information on the fate and behaviour of CPC in on-site treatment plants is needed to 
determine the risk of CPC when used in slaughterhouses discharging their waste water direct to 
surface water via these treatment plants. Based on the current toxicity data, it is estimated that these 
plants need to reach a removal efficacy of more than 99.9% to exclude a risk for surface water.  
In order to improve the robustness and reduce the uncertainty of the assessment, it is recommended to 
the applicant to provide more reliable data on the environmental fate and behaviour of CPC and to 
provide (long-term) tests relevant for the compartments surface water, sediment and soil. This 
additional information would reduce the level of uncertainty of the assessment.  However, considering 
the high level of potential risk indicated by the present assessment, it is the opinion of the CEF Panel 
that the attainment of safe levels would be highly unlikely without suitable measures to reduce 
environmental emissions. An option would be to reduce exposure by achieving a high proportion of 
recycling during treatment in poultry slaughterhouses. 
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6. Conclusions and recommendations 
6.1. Conclusions 
ToR 1. The toxicological safety of the substance 
 This opinion deals with the evaluation of the safety of Cecure® commercial product 
containing CPC as active ingredient, for removal of microbial surface contamination from raw 
poultry carcasses, under the usage conditions specified in this opinion. The safety of CPC 
when used as biocide is outside the remit of CEF Panel.  
 The CEF Panel considered the data on identity, specifications of Cecure® and on stability of 
CPC under the intended conditions of use as sufficient. 
 The available data indicate that CPC, tested as a working diluted solution in Cecure®, is not 
mutagenic in bacteria and not clastogenic in cultured mammalian cells. Negative results were 
also obtained in a gene mutation assay with CPC in mouse lymphoma cells and in limited tests 
in Aspergillus, Tradescantia and Drosophila. The Panel also noted that in addition to these 
consistently negative results, the substance does not contain structural alerts for genotoxicity. 
Thus, based on the available evidence, the CEF Panel considered that there is no concern for 
genotoxicity.  
 The CEF Panel had access to information on subchronic toxicity studies on CPC. From a 
recent 90-day toxicity study in Sprague-Dawley rats, the CEF Panel could identify a NOAEL 
of 18 mg/kg bw/day in rats, based on increased caecum weights noted in males. The CEF 
Panel considered the increase in caecum weight as relevant for risk characterisation of 
Cecure® since CPC, the active component of Cecure®, has been suggested to decrease the 
total number of microorganisms in the caecal contents of rats of both sexes. This led to an 
increase in caecum to body weight ratios which was positively correlated with dietary levels 
of CPC. The CEF Panel considered that a potential similar effect of CPC on human 
gastrointestinal microflora should not be disregarded. 
 The data presented by the applicant allowed the CEF Panel to perform a very conservative risk 
assessment. The potential exposure to CPC was estimated to be up to 5.7 µg/kg bw/day at the 
mean and 17.8 µg/kg bw/day at the 95th percentile of poultry consumption. The potential 
exposure to propylene glycol (PG) by mean and high level consumers such as young children 
would thus be up to 0.5 µg /kg bw/day at the mean and 1.4 µg/ kg bw/day at the 95th percentile 
of treated poultry consumption. These exposure estimates are worst cases since they assumed 
that all poultry carcasses which are going to be consumed have been treated with Cecure®. 
The Panel was not able to assess total exposure of CPC from other potential dietary sources 
and non dietary sources.  
 Taking into account the highest calculated potential conservative exposure estimates to CPC 
from treated poultry consumption, the margins of safety for CPC would be more than 3000 at 
the mean and more than 1000 at the 95th percentile, when compared to the NOAEL of 18 mg 
CPC/kg bw/day, identified by the CEF Panel in a 13-week toxicity study in Sprague-Dawley 
rats. For PG, the margins of safety would be 22000 at the mean and 7000 at the 95th percentile, 
when compared to the Acceptable Daily Intake (ADI) of 0 - 10 mg/kg bw/day allocated by the 
Joint FAO/WHO Expert Committee on Food Additives (JECFA). Furthermore, they would be 
3500 times below the TDI of 5 mg/kg bw/day established by the Scientific Committee on 
Food (SCF) for PG.  
 Therefore based on the toxicological data available, the estimated margins of safety (going 
from three orders of magnitude for CPC to four orders of magnitude for PG) and the 
conservative exposure estimates used to assess CPC exposure from consumption of poultry 
carcasses, the CEF Panel considers that there are no safety concerns for humans from the 
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proposed use of Cecure® for removal of microbial surface contamination from raw poultry 
under the usage conditions specified in this opinion.  
 The CEF Panel is aware that additional data on the toxicology of CPC (including genotoxicity 
and reproductive toxicity) have been generated within the context of data requirements for 
biocides. However these data were not available to EFSA. If these data are made available to 
EFSA in the future, EFSA will take them into account. 
ToR 2. The efficacy, i.e. does the use of the substance significantly reduce the level of 
contamination of pathogenic micro-organisms 
 Both Cecure® and its active ingredient CPC were found efficacious in reducing contamination 
with pathogenic microorganisms on fresh broiler carcasses or chicken skin, when applied on 
pre- or post-chill. 
 Overall microbial reductions achieved on pre- and post-chill treated samples were in the range 
of <1.0 to 5.0 log units over untreated and water-treated controls. 
 Based on a peer reviewed published paper, reporting data from three industrial evaluations, 
Cecure®, applied as proposed in the application on carcasses needing reprocessing, reduced 
Salmonella and Campylobacter relative prevalence by 50-95% and 90-97 %, respectively. 
 The documented microbial reductions by treatment with Cecure® are considered as 
biologically relevant. 
 Additional data are needed to confirm that the concentration of 0.6% CPC was more effective 
than 0.1% CPC, while concentrations above 0.6 % CPC do not further increase microbial 
reductions. The minimum CPC concentration to be applied was not specified.  
 Efficacy appeared not to be affected by volume of solution applied, flow rate, spraying 
pressure, rate of carcass processing, and time of exposure within the ranges examined. 
 Evidence is inadequate to support that the recycled Cecure® solution is as efficacious as the 
fresh solution and does not accumulate resistant bacterial cells and/or spores. 
 Data concerning possible accumulation of spores during recycling and reuse of solution were 
not provided. 
ToR 3. The potential emergence of reduced susceptibility to biocides and/or resistance to 
therapeutic antimicrobials linked to the use of the substance   
 Data to address the issue of the potential emergence of reduced susceptibility to biocides 
and/or resistance to therapeutic antimicrobials linked to the use of CPC have not been 
provided. 
 Data to address the issue of the potential selection of isolates with reduced susceptibility to 
biocides and/or resistance to therapeutic antimicrobials linked to the use of CPC have not been 
provided. 
 There are reports of the development/selection of resistance to biocides and therapeutic 
antibiotics in some organisms following exposure to CPC; the principal mechanism of 
resistance involves upregulation of a multidrug efflux pump. 
 In some pathogenic bacteria the dissemination of antibiotic resistance genes may be facilitated 
by the linkage between such genes and the qac genes. 
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 The development of enzymatic resistance to biocides and/ therapeutic antimicrobials as a 
result of exposure to CPC is highly unlikely. 
 Data provided were not considered useful to support the absence of antimicrobial activity of 
CPC in organic material such as poultry offal. 
ToR 4. The risk related to the release of the slaughterhouse and/or processing plant effluents, 
linked to the intended use of the substance, into the environment   
 Basic data necessary for an assessment of the risk of Cecure® for the environmental 
compartments surface water, sediment and soil, as well as for evaluation of the function of 
sewage treatment plants were not provided or could not be validated.  Additional data relevant 
for the environmental risk assessment of Cecure® have been generated within the context of 
data requirements for biocides. However these data were not available to EFSA. 
 Using data found in the open literature predicted no-effect concentrations (PNEC) for 
protection of the function of sewage treatment plants (STP), for surface water, as well as for 
sediment and soil, could be derived based on the risk assessment methodology applied to 
biocides and industrial chemicals (REACH/TGD).  
 The PEC/PNEC ratios calculated indicate that the use of CPC in poultry slaughterhouses does 
not pose a risk for the function of sewage treatment plants. As there are no indications of a 
high bioaccumulation potential, no risk for birds and mammals in the environment via indirect 
exposure through the food-chain (secondary poisoning) has to be expected.  
 In view of the low vapour pressure, low bioaccumulation potential and the high adsorptive 
properties of CPC, indirect exposure of man via groundwater (as a source for drinking water), 
air and fish is expected to be negligible.  
 Despite the fact that it is assumed that a large proportion of the active ingredient is recycled 
and that the product is assumed to be used in a specific application system claimed by the 
applicant, risks for the environmental compartments surface water, sediment and soil are 
apparent.  
6.2. Recommendations 
 As requested in the guidance (EFSA, 2010), data addressing the potential emergence of and 
selection for reduced susceptibility to biocides and or resistance to therapeutic antimicrobials 
linked to the use of CPC should be provided by the applicant. 
 The minimum CPC concentration applied for should be specified.  
 To assess the safety and efficacy of recycling and reusing the substance, data about possible 
accumulation of bacterial spores, as well as data to support continuous efficacy of the recycled 
material should be collected. 
 In order to improve the robustness and reduce the uncertainty of the environmental risk 
assessment, it is recommended that the applicant provides more reliable data on the fate and 
behaviour of CPC and provides (long-term) tests relevant for the compartments surface water, 
sediment and soil. However, considering the high level of potential risk indicated by the 
present assessment, it is the opinion of the CEF Panel that the attainment of safe levels would 
be highly unlikely without suitable measures to reduce environmental emissions. An option 
would be to reduce exposure by achieving a high proportion of recycling during treatment in 
poultry slaughterhouses. 
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7. Documentation provided to EFSA 
 Dossier in Support of the Use of Cecure® as a Processing Aid for the Decontamination of 
Raw Poultry Products Pursuant to Art. 3(2) of Reg. 853/2004 of European Parliament and 
Council, March 2011 (revised in December 2011), submitted by SAFE FOODS 
CORPORATION  
o Annex A: Cecure® Approval Documentation 
o Annex B: Referenced journal articles and code of federal register 
o Annex C: Experimental protocols – reports from in-house studies 
o Annex D: Technical data sheets and attachments to environmental assessment 
o Annex E: Attachments to food additive petitions 2A4736 (FAP A) and 6A4767 (FAP 
B) 
o Toxicity studies, info on purity, impurities and dosage methods, on residues of CPC 
and updated data on consumer exposure assessment, submitted in October 2011 
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APPENDICES 
A.  TABLE WITH DETAILED DATA OF CECURE® TREATMENT OF RAW POULTRY PRODUCTS OF THE IN-HOUSE STUDIES INCLUDED IN THE ASSESSMENT  
Study Target strains Log10 red 
Treated/ 
untreated 
log CFU/ml 
Log10 red 
Treated/ 
Water 
CFU/ml 
Log10 red 
Water/ 
untreated 
CFU/ml 
Statistical 
significance 
Industrial/
pilot/lab 
Natural 
contamination 
/inoculation 
Meat 
products 
Pre/post 
chill 
% 
CPC 
pressure volume 
(litres / 
bird) 
line speed  
(birds / 
min) 
HIGH STRENGTH OF EVIDENCE 
60302 APC 0.45 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
Pre chill 0.1 NA 0.9 NA 
60302 E.coli 0.51 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
Pre chill 0.1 NA 0.9 NA 
60302 coliforms 0.45 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
Pre chill 0.1 NA 0.9 NA 
60302 APC 0.68 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
Pre chill 0.1 NA 3.8 NA 
60302 E.coli 0.51 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
Pre chill 0.1 NA 3.8 NA 
60302 coliforms 0.45 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
Pre chill 0.1 NA 3.8 NA 
60302 APC 2.59 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
Pre chill 0.6 NA 0.9 NA 
60302 E.coli 2.04 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
Pre chill 0.6 NA 0.9 NA 
60302 coliforms 1.99 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
Pre chill 0.6 NA 0.9 NA 
60302 APC 2.15 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
Pre chill 0.6 NA 3.8 NA 
60302 E.coli 1.54 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
Pre chill 0.6 NA 3.8 NA 
60302 coliforms 1.61 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
Pre chill 0.6 NA 3.8 NA 
60302 APC 1.4 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.1 NA 0.9 NA 
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Study Target strains Log10 red 
Treated/ 
untreated 
log CFU/ml 
Log10 red 
Treated/ 
Water 
CFU/ml 
Log10 red 
Water/ 
untreated 
CFU/ml 
Statistical 
significance 
Industrial/
pilot/lab 
Natural 
contamination 
/inoculation 
Meat 
products 
Pre/post 
chill 
% 
CPC 
pressure volume 
(litres / 
bird) 
line speed  
(birds / 
min) 
60302 E.coli 0.37 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.1 NA 0.9 NA 
60302 coliforms 0.49 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.1 NA 0.9 NA 
60302 APC 2.06 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.1 NA 3.8 NA 
60302 E.coli 0.81 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.1 NA 3.8 NA 
60302 coliforms 0.91 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.1 NA 3.8 NA 
60302 APC 2.05 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.6 NA 0.9 NA 
60302 E.coli 0.81 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.6 NA 0.9 NA 
60302 coliforms 0.95 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.6 NA 0.9 NA 
60302 APC 2.33 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.6 NA 3.8 NA 
60302 E.coli 0.91 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.6 NA 3.8 NA 
60302 coliforms 1.05 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.6 NA 3.8 NA 
60401 APC 1.74 1.53 0.21 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
pre chill 0.05 NA 2.2 35 
60401 E.coli 2.15 0.81 1.34 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
pre chill 0.05 NA 2.2 35 
60401 APC 1.04 0.83 0.21 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
pre chill 0.05 NA 2.2 70 
60401 E.coli 1.53 0.19 1.34 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
pre chill 0.05 NA 2.2 70 
60401 APC 3.54 3.33 0.21 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
pre chill 0.6 NA 2.2 35 
60401 E.coli 2.64 1.3 1.34 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
pre chill 0.6 NA 2.2 35 
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Study Target strains Log10 red 
Treated/ 
untreated 
log CFU/ml 
Log10 red 
Treated/ 
Water 
CFU/ml 
Log10 red 
Water/ 
untreated 
CFU/ml 
Statistical 
significance 
Industrial/
pilot/lab 
Natural 
contamination 
/inoculation 
Meat 
products 
Pre/post 
chill 
% 
CPC 
pressure volume 
(litres / 
bird) 
line speed  
(birds / 
min) 
60401 APC 3.54 3.33 0.21 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
pre chill 0.6 NA 2.2 70 
60401 E.coli 2.64 1.3 1.34 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
pre chill 0.6 NA 2.2 70 
60401 APC 2.98 2.37 0.61 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.05 NA 2.2 35 
60401 E.coli 1.94 1.5 0.44 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.05 NA 2.2 35 
60401 APC 2.36 1.75 0.61 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.05 NA 2.2 70 
60401 E.coli 1.52 0.08 1.44 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.05 NA 2.2 70 
60401 APC 3.23 2.62 0.61 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.6 NA 2.2 35 
60401 E.coli 1.94 1.5 0.44 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.6 NA 2.2 35 
60401 APC 3.23 2.62 0.61 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.6 NA 2.2 70 
60401 E.coli 1.94 1.5 0.44 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.6 NA 2.2 70 
60407 APC 2.14 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.4 NA 2.2 70 
60407 E.coli 1 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.4 NA 2.2 70 
60407 coliforms 1.3 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.4 NA 2.2 70 
60407 APC 2.42 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.4 NA 3 70 
60407 E.coli 1.67 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.4 NA 3 70 
60407 coliforms 1.82 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.4 NA 3 70 
60407 APC 2.3 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.4 NA 4.9 70 
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Study Target strains Log10 red 
Treated/ 
untreated 
log CFU/ml 
Log10 red 
Treated/ 
Water 
CFU/ml 
Log10 red 
Water/ 
untreated 
CFU/ml 
Statistical 
significance 
Industrial/
pilot/lab 
Natural 
contamination 
/inoculation 
Meat 
products 
Pre/post 
chill 
% 
CPC 
pressure volume 
(litres / 
bird) 
line speed  
(birds / 
min) 
60407 E.coli 1.99 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.4 NA 4.9 70 
60407 coliforms 2.06 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.4 NA 4.9 70 
60407 APC 2.01 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.4 NA 5.7 70 
60407 E.coli 0.9 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.4 NA 5.7 70 
60407 coliforms 0.95 NA NA 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
post chill 0.4 NA 5.7 70 
Waldroup 
1999 
APC 0.9 NA NA yes industrial natural 
broiler 
carcass 
post chill 0.25 40-60 psi 0.06-0.12 70-90 
Waldroup 
1999 
E.coli 0.7 NA NA yes industrial natural 
broiler 
carcass 
post chill 0.25 40-60 psi 0.06-0.12 70-90 
Waldroup 
1999 
coliforms 0.7 NA NA yes industrial natural 
broiler 
carcass 
post chill 0.25 40-60 psi 0.06-0.12 70-90 
Waldroup 
1999 
Campylobacter 0.4 NA NA yes industrial natural 
broiler 
carcass 
post chill 0.4 40-60 psi 0.06-0.12 70-90 
Waldroup 
1999 
APC 2 NA NA yes industrial natural 
broiler 
carcass 
post chill 0.4 40-60 psi 0.06-0.12 70-90 
Waldroup 
1999 
E.coli 0.9 NA NA yes industrial natural 
broiler 
carcass 
post chill 0.4 40-60 psi 0.06-0.12 70-90 
Waldroup 
1999 
coliforms 0.8 NA NA yes industrial natural 
broiler 
carcass 
post chill 0.4 40-60 psi 0.06-0.12 70-90 
Waldroup 
1999 
Campylobacter >2 NA NA  industrial natural 
broiler 
carcass 
post chill 0.4 40-60 psi 0.06-0.13 70-90 
Waldroup 
1999 
APC > 99% NA NA yes industrial natural 
broiler 
carcass 
post chill NA 40-60 psi 0.06-0.12 70-90 
Waldroup 
1999 
E.coli > 99% NA NA yes industrial natural 
broiler 
carcass 
post chill NA 40-60 psi 0.06-0.12 70-90 
Waldroup 
1999 
coliforms > 99% NA NA yes industrial natural 
broiler 
carcass 
post chill NA 40-60 psi 0.06-0.12 70-90 
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Study Target strains Log10 red 
Treated/ 
untreated 
log CFU/ml 
Log10 red 
Treated/ 
Water 
CFU/ml 
Log10 red 
Water/ 
untreated 
CFU/ml 
Statistical 
significance 
Industrial/
pilot/lab 
Natural 
contamination 
/inoculation 
Meat 
products 
Pre/post 
chill 
% 
CPC 
pressure volume 
(litres / 
bird) 
line speed  
(birds / 
min) 
Waldroup 
1999 
Campylobacter  NA NA yes industrial natural 
broiler 
carcass 
post chill NA 40-60 psi 0.06-0.12 70-90 
61010 Enterobacteriaceae 2.03 1.71 0.32 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
pre chill 0.2 NA 3.8 70 
61010 APC 3.35 3.01 0.34 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
pre chill 0.2 NA 3.8 70 
61010 Pseudomonas 1.29 0.84 0.45 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
pre chill 0.2 NA 3.8 70 
61010 coliforms 1.87 1.61 0.26 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
pre chill 0.2 NA 3.8 70 
61010 E.coli 1.78 1.53 0.25 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
pre chill 0.2 NA 3.8 70 
61010 Campylobacter 0.93 0.72 0.21 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
pre chill 0.2 NA 3.8 70 
61010 Enterobacteriaceae 2.15 1.83 0.32 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
pre chill 1 NA 3.8 70 
61010 APC 3.72 3.38 0.34 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
pre chill 1 NA 3.8 70 
61010 Pseudomonas 1.51 1.06 0.45 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
pre chill 1 NA 3.8 70 
61010 coliforms 1.96 1.7 0.26 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
pre chill 1 NA 3.8 70 
61010 E.coli 1.85 1.6 0.25 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
pre chill 1 NA 3.8 70 
61010 Campylobacter 0.93 0.72 0.21 
Anova, Tukey‟s 
Kramer 
industrial natural 
broiler 
carcass 
pre chill 1 NA 3.8 70 
70414 E.coli 0.97 NA NA  industrial natural 
broiler 
carcass 
pre chill 0.6 NA NA NA 
060510 APC 2.02 1.41 NA NA industrial natural 
Broiler 
carcass 
Post chill 0.1 NA 0.95 175 
060510 APC 2.48 1.87 NA NA industrial natural 
Broiler 
carcass 
Post chill 0.1 NA 1.5 175 
060510 APC 2.19 1.58 NA NA industrial natural 
Broiler 
carcass 
Post chill 0.1 NA 2.1 175 
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Study Target strains Log10 red 
Treated/ 
untreated 
log CFU/ml 
Log10 red 
Treated/ 
Water 
CFU/ml 
Log10 red 
Water/ 
untreated 
CFU/ml 
Statistical 
significance 
Industrial/
pilot/lab 
Natural 
contamination 
/inoculation 
Meat 
products 
Pre/post 
chill 
% 
CPC 
pressure volume 
(litres / 
bird) 
line speed  
(birds / 
min) 
060510 APC 2.23 1.61 NA NA industrial natural 
Broiler 
carcass 
Post chill 0.1 NA 2.6 175 
060510 APC 2.48 1.87 NA NA industrial natural 
Broiler 
carcass 
Post chill 0.2 NA 0.95 175 
060510 APC 2.48 1.87 NA NA industrial natural 
Broiler 
carcass 
Post chill 0.2 NA 1.5 175 
060510 APC 2.48 1.87 NA NA industrial natural 
Broiler 
carcass 
Post chill 0.2 NA 2.1 175 
060510 APC 2.42 1.81 NA NA industrial natural 
Broiler 
carcass 
Post chill 0.2 NA 2.6 175 
060510 APC 2.48 1.87 NA NA industrial natural 
Broiler 
carcass 
Post chill 0.3 NA 0.95 175 
060510 APC 2.48 1.87 NA NA industrial natural 
Broiler 
carcass 
Post chill 0.3 NA 1.5 175 
060510 APC 2.48 1.87 NA NA industrial natural 
Broiler 
carcass 
Post chill 0.3 NA 2.1 175 
060510 APC 2.48 1.87 NA NA industrial natural 
Broiler 
carcass 
Post chill 0.3 NA 2.6 175 
060510 APC 2.48 1.87 NA NA industrial natural 
Broiler 
carcass 
Post chill 0.4 NA 0.95 175 
060510 APC 2.48 1.87 NA NA industrial natural 
Broiler 
carcass 
Post chill 0.4 NA 1.5 175 
060510 APC 2.48 1.87 NA NA industrial natural 
Broiler 
carcass 
Post chill 0.4 NA 2.1 175 
060510 APC 2.48 1.87 NA NA industrial natural 
Broiler 
carcass 
Post chill 0.4 NA 2.6 175 
HIGH-MEDIUM STRENGTH OF EVIDENCE 
Contact time: 3 sec 
Waldroup 
2000a 
APC 1.36 1.09 0.27 
General Linear 
Model 
pilot natural 
broiler 
carcass 
pre chill 0.2 NA 0.29 NA 
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Study Target strains Log10 red 
Treated/ 
untreated 
log CFU/ml 
Log10 red 
Treated/ 
Water 
CFU/ml 
Log10 red 
Water/ 
untreated 
CFU/ml 
Statistical 
significance 
Industrial/
pilot/lab 
Natural 
contamination 
/inoculation 
Meat 
products 
Pre/post 
chill 
% 
CPC 
pressure volume 
(litres / 
bird) 
line speed  
(birds / 
min) 
Waldroup 
2000a 
E.coli 0.68 0.3 0.38 
General Linear 
Model 
pilot natural 
broiler 
carcass 
pre chill 0.2 NA 0.29 NA 
Waldroup 
2000a 
coliforms 0.6 0.72 -0.12 
General Linear 
Model 
pilot natural 
broiler 
carcass 
pre chill 0.2 NA 0.29 NA 
Waldroup 
2000a 
Campylobacter 1.71 0.99 0.72 
General Linear 
Model 
pilot natural 
broiler 
carcass 
pre chill 0.2 NA 0.29 NA 
Waldroup 
2000a 
APC 1.91 1.64 0.27 
General Linear 
Model 
pilot natural 
broiler 
carcass 
pre chill 0.5 NA 0.29 NA 
Waldroup 
2000a 
E.coli 0.72 0.34 0.38 
General Linear 
Model 
pilot natural 
broiler 
carcass 
pre chill 0.5 NA 0.29 NA 
Waldroup 
2000a 
coliforms 0.76 0.88 -0.12 
General Linear 
Model 
pilot natural 
broiler 
carcass 
pre chill 0.5 NA 0.29 NA 
Waldroup 
2000a 
Campylobacter 2.25 1.53 0.72 
General Linear 
Model 
pilot natural 
broiler 
carcass 
pre chill 0.5 NA 0.29 NA 
Contact time: 10 sec 
Waldroup 
2000a 
APC 1.6 1.33 0.27 
General Linear 
Model 
pilot natural 
broiler 
carcass 
pre chill 0.2 NA 0.29 NA 
Waldroup 
2000a 
E.coli 0.54 0.16 0.38 
General Linear 
Model 
pilot natural 
broiler 
carcass 
pre chill 0.2 NA 0.29 NA 
Waldroup 
2000a 
coliforms 0.65 0.77 -0.12 
General Linear 
Model 
pilot natural 
broiler 
carcass 
pre chill 0.2 NA 0.29 NA 
Waldroup 
2000a 
Campylobacter 2.25 1.53 0.72 
General Linear 
Model 
pilot natural 
broiler 
carcass 
pre chill 0.2 NA 0.29 NA 
Waldroup 
2000a 
APC 2.83 2.56 0.27 
General Linear 
Model 
pilot natural 
broiler 
carcass 
pre chill 0.5 NA 0.29 NA 
Waldroup 
2000a 
E.coli 0.97 0.59 0.38 
General Linear 
Model 
pilot natural 
broiler 
carcass 
pre chill 0.5 NA 0.29 NA 
Waldroup 
2000a 
coliforms 1.18 1.3 -0.12 
General Linear 
Model 
pilot natural 
broiler 
carcass 
pre chill 0.5 NA 0.29 NA 
Waldroup 
2000a 
Campylobacter 2.34 1.62 0.72 
General Linear 
Model 
pilot natural 
broiler 
carcass 
pre chill 0.5 NA 0.29 NA 
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Study Target strains Log10 red 
Treated/ 
untreated 
log CFU/ml 
Log10 red 
Treated/ 
Water 
CFU/ml 
Log10 red 
Water/ 
untreated 
CFU/ml 
Statistical 
significance 
Industrial/
pilot/lab 
Natural 
contamination 
/inoculation 
Meat 
products 
Pre/post 
chill 
% 
CPC 
pressure volume 
(litres / 
bird) 
line speed  
(birds / 
min) 
MEDIUM STRENGTH OF EVIDENCE 
60613 APC 2.27 1.98 0.29 NA pilot inoculated 
broiler 
carcass 
post chill 0.2 NA 0.95 160 
60613 E.coli 2.47 2.16 0.31 NA pilot inoculated 
broiler 
carcass 
post chill 0.2 NA 0.95 160 
60613 Salmonella 3.44 2.83 0.61 NA pilot inoculated 
broiler 
carcass 
post chill 0.2 NA 0.95 160 
60613 APC 5.13 4.84 0.29 NA pilot inoculated 
broiler 
carcass 
post chill 0.4 NA 0.95 160 
60613 E.coli 4.91 4.6 0.31 NA pilot inoculated 
broiler 
carcass 
post chill 0.4 NA 0.95 160 
60613 Salmonella 4.4 3.79 0.61 NA pilot inoculated 
broiler 
carcass 
post chill 0.4 NA 0.95 160 
60613 APC 6.01 5.72 0.29 NA pilot inoculated 
broiler 
carcass 
post chill 0.6 NA 0.95 160 
60613 E.coli 5.14 4.83 0.31 NA pilot inoculated 
broiler 
carcass 
post chill 0.6 NA 0.95 160 
60613 Salmonella 5.64 5.03 0.61 NA pilot inoculated 
broiler 
carcass 
post chill 0.6 NA 0.95 160 
60613 APC 6.19 5.9 0.29 NA pilot inoculated 
broiler 
carcass 
post chill 0.6 NA 1.9 160 
60613 E.coli 5.14 4.83 0.31 NA pilot inoculated 
broiler 
carcass 
post chill 0.6 NA 1.9 160 
60613 Salmonella 5.64 5.03 0.61 NA pilot inoculated 
broiler 
carcass 
post chill 0.6 NA 1.9 160 
60613 APC 6.22 5.93 0.29 NA pilot inoculated 
broiler 
carcass 
post chill 0.8 NA 0.95 160 
60613 E.coli 5.14 4.83 0.31 NA pilot inoculated 
broiler 
carcass 
post chill 0.8 NA 0.95 160 
60613 Salmonella 5.64 5.03 0.61 NA pilot inoculated 
broiler 
carcass 
post chill 0.8 NA 0.95 160 
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Study Target strains Log10 red 
Treated/ 
untreated 
log CFU/ml 
Log10 red 
Treated/ 
Water 
CFU/ml 
Log10 red 
Water/ 
untreated 
CFU/ml 
Statistical 
significance 
Industrial/
pilot/lab 
Natural 
contamination 
/inoculation 
Meat 
products 
Pre/post 
chill 
% 
CPC 
pressure volume 
(litres / 
bird) 
line speed  
(birds / 
min) 
60613 APC 6.36 6.07 0.29 NA pilot inoculated 
broiler 
carcass 
post chill 0.8 NA 1.9 160 
60613 E.coli 5.14 4.83 0.31 NA pilot inoculated 
broiler 
carcass 
post chill 0.8 NA 1.9 160 
60613 Salmonella 5.64 5.03 0.61 NA pilot inoculated 
broiler 
carcass 
post chill 0.8 NA 1.9 160 
60613 APC 6.33 6.04 0.29 NA pilot inoculated 
broiler 
carcass 
post chill 1 NA 0.95 160 
60613 E.coli 5.14 4.83 0.31 NA pilot inoculated 
broiler 
carcass 
post chill 1 NA 0.95 160 
60613 Salmonella 5.64 5.03 0.61 NA pilot inoculated 
broiler 
carcass 
post chill 1 NA 0.95 160 
60613 APC 6.3 6.01 0.29 NA pilot inoculated 
broiler 
carcass 
post chill 1 NA 1.9 160 
60613 E.coli 5.11 4.8 0.31 NA pilot inoculated 
broiler 
carcass 
post chill 1 NA 1.9 160 
60613 Salmonella 5.64 5.03 0.61 NA pilot inoculated 
broiler 
carcass 
post chill 1 NA 1.9 160 
60607 APC 1.35 0.69 0.66 NA pilot inoculated 
broiler 
carcass 
post chill 0.2 NA 0.95 160 
60607 E.coli 1.39 0.48 0.91 NA pilot inoculated 
broiler 
carcass 
post chill 0.2 NA 0.95 160 
60607 coliforms 1.59 0.81 0.78 NA pilot inoculated 
broiler 
carcass 
post chill 0.2 NA 0.95 160 
60607 APC 2.25 1.59 0.66 NA pilot inoculated 
broiler 
carcass 
post chill 0.4 NA 0.95 160 
60607 E.coli 2.69 1.78 0.91 NA pilot inoculated 
broiler 
carcass 
post chill 0.4 NA 0.95 160 
60607 coliforms 2.68 1.9 0.78 NA pilot inoculated 
broiler 
carcass 
post chill 0.4 NA 0.95 160 
60607 APC 4.29 3.63 0.66 NA pilot inoculated 
broiler 
carcass 
post chill 0.6 NA 0.95 160 
60607 E.coli 4.03 3.12 0.91 NA pilot inoculated 
broiler 
carcass 
post chill 0.6 NA 0.95 160 
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Study Target strains Log10 red 
Treated/ 
untreated 
log CFU/ml 
Log10 red 
Treated/ 
Water 
CFU/ml 
Log10 red 
Water/ 
untreated 
CFU/ml 
Statistical 
significance 
Industrial/
pilot/lab 
Natural 
contamination 
/inoculation 
Meat 
products 
Pre/post 
chill 
% 
CPC 
pressure volume 
(litres / 
bird) 
line speed  
(birds / 
min) 
60607 coliforms 4.02 3.24 0.78 NA pilot inoculated 
broiler 
carcass 
post chill 0.6 NA 0.95 160 
60607 APC 4.51 3.85 0.66 NA pilot inoculated 
broiler 
carcass 
post chill 0.6 NA 1.9 160 
60607 E.coli 4.43 3.52 0.91 NA pilot inoculated 
broiler 
carcass 
post chill 0.6 NA 1.9 160 
60607 coliforms 4.43 3.65 0.78 NA pilot inoculated 
broiler 
carcass 
post chill 0.6 NA 1.9 160 
60607 APC 4.92 4.26 0.66 NA pilot inoculated 
broiler 
carcass 
post chill 0.8 NA 0.95 160 
60607 E.coli 4.48 3.57 0.91 NA pilot inoculated 
broiler 
carcass 
post chill 0.8 NA 0.95 160 
60607 coliforms 4.52 3.74 0.78 NA pilot inoculated 
broiler 
carcass 
post chill 0.8 NA 0.95 160 
60607 APC 4.85 4.19 0.66 NA pilot inoculated 
broiler 
carcass 
post chill 0.8 NA 1.9 160 
60607 E.coli 4.45 3.54 0.91 NA pilot inoculated 
broiler 
carcass 
post chill 0.8 NA 1.9 160 
60607 coliforms 4.49 3.71 0.78 NA pilot inoculated 
broiler 
carcass 
post chill 0.8 NA 1.9 160 
60607 APC 5.04 4.38 0.66 NA pilot inoculated 
broiler 
carcass 
post chill 1 NA 0.95 160 
60607 E.coli 4.65 3.74 0.91 NA pilot inoculated 
broiler 
carcass 
post chill 1 NA 0.95 160 
60607 coliforms 4.7 3.92 0.78 NA pilot inoculated 
broiler 
carcass 
post chill 1 NA 0.95 160 
60607 APC 4.58 3.92 0.66 NA pilot inoculated 
broiler 
carcass 
post chill 1 NA 1.9 160 
60607 E.coli 4.6 3.69 0.91 NA pilot inoculated 
broiler 
carcass 
post chill 1 NA 1.9 160 
60607 coliforms 4.56 3.78 0.78 NA pilot inoculated 
broiler 
carcass 
post chill 1 NA 1.9 160 
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B.   TABLE WITH DETAILED DATA OF CECURE® TREATMENT OF RAW POLUTRY PRODUCTS OF THE PEER-REVIEWED PAPERS INCLUDED IN THE 
ASSESSMENT  
Study Target strains Log10 red 
Treated/ 
untreated 
log CFU/ml 
Log10 red 
Treated/ 
Water 
CFU/ml 
Log10 red 
Water/ 
untreated 
CFU/ml 
Stat signif Industrial/
pilot/lab 
Natural 
contam 
/inoculat
ion 
Meat products Pre/post 
chill 
% 
CPC 
pressure volume 
(litres / 
bird) 
line speed  
(birds / 
min) 
Baker et al. 
2010 
APC 0.5-1       Industrial  
boneless skinless breast 
meat, thighs, wings, split 
breasts, leg quarters and 
whole carcasses 
post chill 0.3 na 1.89   
Beers et al. 
2006 
APC 2.5 1.8 0.7 Yes Industrial  
broiler carcass (on-line 
reprocessing) 
Pre-chill 
0.5-
0.7% 
  
2 to 3.3 
oz./pound  
70 
Beers et al. 
2006 
APC 3.4 3.8 0.4 Yes Industrial  
broiler carcass (on-line 
reprocessing) 
Pre-chill 
0.5-
0.7% 
  
3 to 3.3 
oz./pound  
11-52 
Beers et al. 
2006 
APC 3.9 3.7 0.2 Yes Industrial  
broiler carcass (on-line 
reprocessing) 
Pre-chill 
0.5-
0.7% 
  
4 to 3.3 
oz./pound  
70 
Beers et al. 
2006 
E. coli 1.6 1.1 0.5 Yes Industrial  
broiler carcass (on-line 
reprocessing) 
Pre-chill 
0.5-
0.7% 
  
5 to 3.3 
oz./pound  
70 
Beers et al. 
2006 
E. coli 2.1 2.6 0.5 Yes Industrial  
broiler carcass (on-line 
reprocessing) 
Pre-chill 
0.5-
0.7% 
  
6 to 3.3 
oz./pound  
11-52 
Beers et al. 
2006 
E. coli 2.9 2.7 0.2 Yes Industrial  
broiler carcass (on-line 
reprocessing) 
Pre-chill 
0.5-
0.7% 
  
7 to 3.3 
oz./pound  
70 
Beers et al. 
2006 
Total coliforms 1.2 0.7 0.5 Yes Industrial  
broiler carcass (on-line 
reprocessing) 
Pre-chill 
0.5-
0.7% 
  
8 to 3.3 
oz./pound  
70 
Beers et al. 
2006 
Total coliforms 1.8 2.3 0.5 Yes Industrial  
broiler carcass (on-line 
reprocessing) 
Pre-chill 
0.5-
0.7% 
  
9 to 3.3 
oz./pound  
11-52 
Beers et al. 
2006 
Total coliforms 2.7 2.6 0.1 Yes Industrial  
broiler carcass (on-line 
reprocessing) 
Pre-chill 
0.5-
0.7% 
  
10 to 3.3 
oz./pound  
70 
Beers et al. 
2006 
Campylobacter 1.2 0.6 0.6 Yes Industrial  
broiler carcass (on-line 
reprocessing) 
Pre-chill 
0.5-
0.7% 
  
11 to 3.3 
oz./pound  
70 
Beers et al. 
2006 
Campylobacter 0.8 1.2 0.4 Yes Industrial  
broiler carcass (on-line 
reprocessing) 
Pre-chill 
0.5-
0.7% 
  
12 to 3.3 
oz./pound  
11-52 
Beers et al. 
2006 
Campylobacter 2.1 2.1 0 Yes Industrial  
broiler carcass (on-line 
reprocessing) 
Pre-chill 
0.5-
0.7% 
  
13 to 3.3 
oz./pound  
70 
Beers et al. 
2006 
Salmonella       Yes Industrial  
broiler carcass (on-line 
reprocessing) 
Pre-chill 
0.5-
0.7% 
  
14 to 3.3 
oz./pound  
70 
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Study Target strains Log10 red 
Treated/ 
untreated 
log CFU/ml 
Log10 red 
Treated/ 
Water 
CFU/ml 
Log10 red 
Water/ 
untreated 
CFU/ml 
Stat signif Industrial/
pilot/lab 
Natural 
contam 
/inoculat
ion 
Meat products Pre/post 
chill 
% 
CPC 
pressure volume 
(litres / 
bird) 
line speed  
(birds / 
min) 
Beers et al. 
2006 
Salmonella       Yes Industrial  
broiler carcass (on-line 
reprocessing) 
Pre-chill 
0.5-
0.7% 
  
15 to 3.3 
oz./pound  
11-52 
Beers et al. 
2006 
Salmonella       Yes Industrial  
broiler carcass (on-line 
reprocessing) 
Pre-chill 
0.5-
0.7% 
  
16 to 3.3 
oz./pound  
70 
Breen et al 
1997 
Salmonella 
Typhimurium 
0.59*     Anova lab  Chicken skin   
1, 2, 
4, 8%  
  
5 ml/6.25 
cm2 
  
Arritt et al 
2002 
Campylobacter 2.89     
Tukey's 
HSD 
lab  Chicken skin   
0.1% 
- 
0.5% 
8 psi     
Li et al. 
1997 
Salmonella 
Typhimurium 
  0.46**   Anova Pilot  broiler carcass Pre chill 
0.10
%(30 
sec) 
207 kPa     
Li et al. 
1997 
Salmonella 
Typhimurium 
  0.5**   Anova Pilot  broiler carcass Pre chill 
0.10
%(30 
sec) 
345 kPa     
Li et al. 
1997 
Salmonella 
Typhimurium 
  0.85**   Anova Pilot  broiler carcass Pre chill 
0.10
%(30 
sec) 
827 kPa     
Li et al. 
1997 
Salmonella 
Typhimurium 
  0.97**   Anova Pilot  broiler carcass Pre chill 
0.10
% (90 
sec) 
207 kPa     
Li et al. 
1997 
Salmonella 
Typhimurium 
  0.96**   Anova Pilot  broiler carcass Pre chill 
0.10
% (90 
sec)  
345 kPa     
Li et al. 
1997 
Salmonella 
Typhimurium 
  1.63**   Anova Pilot  broiler carcass Pre chill 
0.10
% (90 
sec)  
827 kPa     
*(cfu/2.5cm2) 
** cfu/bird 
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C.  GLOSSARY AND ABBREVIATIONS 
 
ADI Acceptable Daily Intake 
APC Aerobic Plate Count 
BOD Biological Oxygen Demand 
bw Body weight 
cfu Colony Forming Units 
DAF Dissolved air flotation 
EPM Equilibrium partitioning method 
GHP Good Hygienic Practices 
HACCP Hazard Analysis Critical Control Point 
Eb Enterobacteriaceae 
EC50 Effect concentration on 50% of the tested animals 
Kd (Solids-water) Adsorption coefficient  
Kf Adsorption capacity factor 
LC50 Lethal concentration to 50% of tested animals 
log Koc Logarithm of the soil organic carbon partition coefficient 
log Kow Logarithm of the octanol/water partition coefficient 
PEC Predicted environmental concentration 
PNEC Predicted no effect concentration 
QAC Quaternary ammonium compounds 
Salm Salmonella 
STEC Shigatoxin-producing Escherichia coli 
STP Sewage treatment plant 
VTEC Verotoxigenic Escherichia coli 
 
 
